METHODS FOR TREATING KERATIN FIBERS IN A DYEING PROCESS

Abstract

METHODS FOR TREATING KERATIN FIBERS IN A DYEING PROCESS The disclosure relates to methods for treating keratin fibers. The methods comprise treating the keratin fibers with treatment compositions in connection with a hair dyeing process, the treatment compositions comprising (a) at least one amino acid, (b) at least one osmolyte, (c) at least one carboxylic acid, and (d) at least one solvent. Figure for abstract: none

Description

Title of the invention: METHODS FOR TREATING KERATIN FIBERS IN A DYEING PROCESS Technical field

[0001] The present disclosure relates to methods of treating keratin fibers, such as hair, for example repairing damaged keratin fibers, providing strength to the keratin fibers and / or reducing the elasticity of the keratin fibers, in connection with a process of dyeing the keratin fibers. BACKGROUND

[0002] Consumers use cosmetic compositions and processes to change or enhance the appearance of their hair, for example, by changing the color, style, and / or shape of the hair, and / or by imparting various properties to the hair, such as shine and conditioning. However, many compositions and processes for changing the appearance of hair, such as compositions and processes for permanently changing hair color, involve harsh chemical treatments. For example, compositions and processes for changing hair color typically require the presence of harsh chemical compounds, such as oxidizing agents. In order to change the color of the hair, these components must first break down the natural components of the hair fibers.

[0003] It is known that, although such processes effectively alter hair color, the chemical agents used inherently cause hair damage and negatively impact the strength, elasticity, and porosity of the hair fibers. For example, hair that has been bleached, dyed, repeatedly styled, etc., is often dry, frizzy, and generally unpleasant to the touch and appearance. In addition, damaged hair is brittle and / or exhibits increased elasticity, resulting in more frequent hair breakage. As such, consumers are seeking compositions and processes to prevent or minimize such damage and / or to repair hair that has been damaged by such treatments and processes.In particular, consumers want hair that is strong, does not break easily, can be stretched or manipulated while retaining the ability to return to its original state without breaking (i.e., reduced elasticity), feels soft and healthy, and also looks shiny and healthy.

[0004] However, it has proven difficult to formulate compositions that satisfactorily meet these wishes. For example, some compositions that Attempts to provide a solution only coat the hair with compounds that can improve the feel and appearance of the hair; however, this approach is only temporary and superficial. Rather than preventing or repairing hair damage, this approach simply masks the damage until the next rinse or wash. Other compositions attempt to treat damage within the hair fiber, but to date, they have not been satisfactory.

[0005] The present inventors have now discovered a synergistic combination of components that is surprisingly effective in preventing or minimizing hair damage and treating damaged hair. Hair treated with compositions according to the disclosure exhibits surprisingly reduced signs of damage, including increased strength and / or reduced elasticity, particularly hair that has been damaged by harsh chemical treatments, such as dyeing. SUMMARY

[0006] The present disclosure relates to methods of treating keratin fibers, e.g., human hair, for example, to prevent, minimize, and / or repair hair damage, such as damage caused by hair dyeing compositions and processes. Compositions that may be used in the methods according to the disclosure ("treatment compositions") comprise a synergistic combination of one or more amino acids, one or more osmolytes, and one or more carboxylic acids, and the methods comprise applying a treatment composition according to the disclosure to the keratin fibers in connection with a hair dyeing process.

[0007] In various embodiments, hair treatment compositions that may be used in the methods of the disclosure comprise (a) at least one amino acid, (b) at least one osmolyte, (c) at least one carboxylic acid, and (d) optionally at least one solvent. The pH of the treatment compositions is generally less than 7, or less than about 6, for example, from about 2 to about 5, or from about 3 to about 4.

[0008] In some embodiments, the treatment compositions that can be used in the methods according to the disclosure comprise at least one amino acid selected from basic amino acids, for example, arginine, histidine, lysine, their salts, or combinations thereof. In various embodiments, the total amount of basic amino acids and their salts ranges from about 0.1% to about 15%, preferably from about 1% to about 12%, more preferably from about 2% to about 10%, more preferably from about 3% to about 7%, and most preferably from about 4% to about 6% by weight, based on the total weight of the composition. In other embodiments, the compositions comprise at least at least one amino acid selected from acidic or neutral amino acids and their salts, for example serine. In various embodiments, the total amount of acidic and / or neutral amino acids and their salts ranges from about 0.01% to about 5%, preferably from about 0.05% to about 4%, more preferably from about 0.1% to about 3%, and most preferably from about 0.25% to about 2.5% by weight, based on the total weight of the composition. In still other embodiments, the compositions comprise a mixture of basic, acidic and / or neutral amino acids, for example the compositions may comprise arginine and serine.In various embodiments, the total amount of amino acids and their salts present in the composition ranges from about 0.1% to about 15%, preferably from about 1% to about 12%, more preferably from about 2% to about 10%, more preferably from about 3% to about 7%, and most preferably from about 4% to about 6% by weight, based on the total weight of the composition.

[0009] In certain preferred embodiments, the compositions that may be used in the methods comprise one or more amino acids selected from glycine, proline, methionine, serine, arginine, lysine, histidine, salts of any of these (particularly, alkali metal, alkaline earth metal or zinc salts), and combinations of two or more thereof.

[0010] In various embodiments, the treatment compositions comprise at least one osmolyte selected from carbohydrate sugars, methylsulfonium compounds, polyamines, and / or amino acid derivatives such as betaines, preferably selected from the compounds of formula (II). In various embodiments, the total amount of osmolytes present in the treatment composition ranges from about 0.01% to about 10%, preferably from about 1% to about 5%, more preferably from about 1.25% to about 4%, more preferably from about 1.5% to about 3%, and most preferably from about 2% to about 2.5% by weight, based on the total weight of the composition.In various embodiments, the treatment composition has a weight ratio of total amino acid to total osmolyte that is greater than or equal to about 0.5, such as greater than about 1, preferably from about 1.25 to about 3.5, more preferably from about 1.5 to about 3, more preferably from about 1.75 to about 2.5, and most preferably from about 1.75 to about 2.25.

[0011] In various embodiments, the at least one carboxylic acid is selected from oxalic acid, malonic acid, glutaric acid, succinic acid, adipic acid, glycolic acid, citric acid, tartaric acid, malic acid, maleic acid, lactic acid, their salts, or combinations of two or more thereof. ci, and preferably citric acid, lactic acid, their salts, or combinations of two or more thereof. In various embodiments, the total amount of carboxylic acids and their salts may range from about 0.5% to about 20%, preferably from about 1% to about 15%, more preferably from about 2% to about 12%, more preferably from about 3% to about 10%, and most preferably from about 4% to about 7% by weight, based on the total weight of the composition. In various embodiments, the treatment composition has a weight ratio of the total amount of amino acids and their salts to the total amount of carboxylic acids and their salts greater than about 0.5, such as greater than about 0.7, preferably from about 0.75 to about 2, and more preferably from about 0.8 to about 1.5.

[0012] The solvent may comprise water and / or at least one non-aqueous solvent and, in some embodiments, comprises water and at least one non-aqueous solvent. Optionally, the treatment compositions comprise water and at least one non-aqueous solvent, preferably selected from polyols, and have a total amount of non-aqueous solvents ranging from about 1% to about 20%, preferably from about 5% to about 20%, more preferably from about 5% to about 15%, and most preferably from about 8% to about 12% by weight, based on the total weight of the composition.

[0013] The treatment compositions that can be used in the methods according to the disclosure may optionally also include at least one additional component selected from fatty compounds, surfactants, thickening agents, or combinations of two or more thereof.

[0014] In some embodiments, the treatment compositions that can be used in the methods according to the disclosure comprise (a) at least one amino acid and / or a salt thereof, (b) at least one betaine, preferably at least one compound of formula (II), for example glycine betaine, in an amount ranging from about 1% to about 5% by weight, based on the total weight of the composition, (c) at least one carboxylic acid and / or a salt thereof, (d) at least one solvent, and (e) optionally at least one additional component selected from fatty compounds, surfactants, thickening agents, or combinations thereof.For example, in at least some embodiments, the treatment composition comprises arginine and the total amount of amino acids ranges from about 1% to about 10% by weight, based on the total weight of the composition, and wherein the total amount of carboxylic acids ranges from about 0.5% to about 20% by weight, based on the total weight of the composition. The pH of the treatment compositions is generally less than 7, for example, ranging from about 2 to about 5, or from about 3 to about 4. In various embodiments, the total amount of non-solvents. aqueous ranges from about 1% to about 20%, preferably from about 2% to about 18%, more preferably from about 3% to about 15%, and most preferably from about 4% to about 12% by weight, relative to the total weight of the composition. In some embodiments, the treatment composition has a weight ratio of the total amount of amino acids and their salts, for example, arginine, serine, their salts, or combinations thereof, to the total amount of betaines, preferably selected from compounds of formula (II) and their salts, for example, glycine betaine, which is greater than or equal to about 0.5, such as greater than about 1, preferably from about 1.25 to about 3.5, more preferably from about 1.5 to about 3, more preferably from about 1.75 to about 2.5, and most preferably from about 1.75 to about 2.25.In some embodiments, the treatment composition has a weight ratio of the total amount of amino acids and their salts to the total amount of carboxylic acids and their salts that is greater than about 0.5 or greater than about 0.7, preferably from about 0.75 to about 2, and more preferably from about 0.8 to about 1.5.

[0015] In preferred embodiments, the treatment compositions comprise (a) at least one amino carboxylic acid or one of its salts, preferably selected from arginine and / or one of its salts, (b) at least one betaine derivative, preferably selected from glycine betaine, (c) at least one carboxylic acid, preferably selected from citric acid, lactic acid and / or their salts, and (d) water. For example, the composition may comprise (a) from about 2% to about 6% arginine and / or a salt thereof, (b) from about 0.5% to about 3.5% glycine betaine, (c) at least one carboxylic acid, preferably selected from citric acid, lactic acid and / or their salts, (d) water and at least one non-aqueous solvent, and (e) optionally serine, wherein the total amount of carboxylic acids and their salts is from about 2% to about 10%, and wherein all amounts are by weight, based on the total weight of the composition.The pH of the treatment compositions is generally less than 7, for example, ranging from about 2 to about 5, or from about 3 to about 4. In various embodiments, the total amount of non-aqueous solvents ranges from about 1% to about 20%, preferably from about 2% to about 18%, more preferably from about 3% to about 15%, and most preferably from about 4% to about 12% by weight, based on the total weight of the composition. In some embodiments, the treatment composition has a weight ratio of the total amount of amino acids and their salts to glycine betaine of greater than about 0.5, such as greater than about 1, preferably from about 1.25 to about 3.5, more preferably from about 1.5 to about 3, more preferably from about 1.75 to about 2.5, and most preferably from about 1.75 to about 2.25. In some embodiments, the composition . treatment has a weight ratio of the total amount of amino acids and their salts to the total amount of carboxylic acids and their salts greater than about 0.5, such as greater than about 0.7, preferably from about 0.75 to about 2, more preferably from about 0.8 to about 1.5. In some embodiments, the compositions include at least one additional component selected from fatty compounds, surfactants, thickening agents, or combinations thereof. If present, the compositions comprise serine in an amount of from about 0.01% to about 2%, preferably from about 0.05% to about 1.5%, more preferably from about 0.05% to about 1%, and most preferably from about 0.05% to about 0.5% by weight, based on the total weight of the composition.When the compositions comprise serine, the compositions may optionally have a weight ratio of total amino acids to serine of greater than about 2, preferably from about 2 to about 15, more preferably from about 4 to about 14, more preferably from about 6 to about 13, and most preferably from about 8 to about 12. When the compositions comprise serine, the compositions may optionally have a weight ratio of glycine betaine to serine of greater than about 2, preferably from about 2 to about 10, more preferably from about 3 to about 8, more preferably from about 3.5 to about 7, and most preferably from about 4 to about 6.

[0016] The methods comprise applying a treatment composition according to the disclosure to keratin fibers in connection with a hair dyeing process. In various embodiments, the methods comprise applying a treatment composition to the hair before and / or after applying a dye composition to the hair, with or without rinsing between applying the treatment composition and the dye composition. The treatment composition may also be applied to the hair concurrently with a dye composition, for example by mixing the treatment composition and the dye composition prior to applying the mixture to the hair, or by separately applying the treatment composition and the dye composition to the hair at the same time.The dyeing compositions that are used according to the disclosure are not limited, and may be those typically used for dyeing hair, for example, oxidative dyeing compositions comprising oxidizing agents and oxidative dyeing compounds. BRIEF DESCRIPTION OF THE FIGURES

[0017] [Fig.lA] [Fig.lB] Figures 1A and 1B show the structures of certain examples of osmolytes that may be included in the compositions according to the disclosure. DETAILED DESCRIPTION

[0018] The disclosure relates to methods of treating keratin fibers, such as hair, for example to repair damaged keratin fibers, provide strength to the keratin fibers and / or reduce the elasticity of the keratin fibers, in connection with a process of dyeing the keratin fibers. I. TREATMENT COMPOSITIONS

[0019] The treatment compositions comprise (a) at least one amino acid, (b) at least one osmolyte, (c) at least one carboxylic acid, and (d) optionally at least one solvent. The treatment compositions may optionally comprise one or more additional components. Amino acids

[0020] The treatment compositions that may be used in the methods according to the disclosure comprise at least one amino acid. Optionally, in various embodiments, the treatment compositions according to the disclosure may comprise one, two, three, or more amino acids. The amino acids that may be selected include those that are basic, acidic, or neutral at neutral pH. In preferred embodiments, the compositions include at least one basic amino acid.

[0021] As used herein, the term "amino acid" includes amino carboxylic acids and their salts, as well as amino sulfonic acids and their salts. As used herein, amino acids mean organic compounds containing a carboxylic acid group (-COOH) (amino carboxylic acids) and / or a sulfonic acid group (—S(=O)2-OH) (amino sulfonic acids) and an amino group (—NH2) which may be primary or secondary, or may be intracyclic, as well as a side chain (R group) specific to each amino acid.

[0022] Aminocarboxylic acids that may be selected include, for example, alanine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine, and combinations of two or more thereof. Examples of aminosulfonic acids include aminomethanesulfonic acid, 2-aminoethanesulfonic acid (taurine), aminopropanesulfonic acid, aminobutanesulfonic acid, aminohexanesulfonic acid, aminoisopropylsulfonic acid, aminododecylsulfonic acid, aminobenzenesulfonic acid, aminotoluenesulfonic acid, sulfanilic acid, chlorosulfanilic acid, diaminobenzenesulfonic acid, aminophenolsulfonic acid, aminopropylbenzenesulfonic acid, aminohexylbenzenesulfonic acid, and combinations of two or more thereof.

[0023] Amino acid salts are also included in the term "amino acid", whether indicated or not. By way of non-limiting example, salts that may be selected include salts with organic or inorganic bases, for example alkali metal salts, such as lithium, sodium or potassium salts; alkaline earth metal salts, such as magnesium or calcium salts; and zinc salts.

[0024] Further, the amino acids may be of D, L, or DL ​​configuration. In certain preferred embodiments, it is advantageous to select amino acids of L configuration, for example, L-proline, L-methionine, L-serine, L-arginine, L-lysine, or combinations of two or more thereof.

[0025] In certain embodiments, it is particularly advantageous to select one or more aminocarboxylic acids. Thus, in various embodiments, the treatment compositions according to the disclosure comprise one or more amino acids of formula (I): COOH (I) H....... C ........N(H), R

[0026] in which:

[0027] - p is an integer equal to 1 or 2, and

[0028] • when p = 1, R forms, together with the nitrogen atom, a saturated heterocycle comprising from 5 to 8 ring members, preferably 5 ring members, this ring possibly being substituted with one or more groups chosen from a hydroxyl or an alkyl (C1-C4); or

[0029] • when p = 2, R represents a hydrogen atom or an alkyl group (C1-C12) saturated, linear or branched, preferably an alkyl group (C1-C4), optionally interrupted by one or more heteroatoms or groups selected from -S-, -NH- or -C(NH)-, and / or optionally substituted with one or more groups selected from hydroxyl (-OH), amino (-NH2), -SH, -COOH, -CONH2, NH-C(NH)-NH2, or an imidazole ring.

[0030] In certain embodiments, when p = 1, R forms, together with the nitrogen atom, a saturated heterocycle comprising 5 ring members, this ring not being substituted.

[0031] In some embodiments, when p = 2, R represents a hydrogen atom or a saturated, straight or branched (C1-C4) alkyl group, optionally substituted with one or more groups selected from hydroxyl (-OH), amino (-NH2), -CONH2, -NH-C(NH)-NH2, or an imidazole ring. In some embodiments, p is preferably 2.

[0032] In some embodiments, the treatment compositions comprise one or more amino acids selected from glycine, proline, methionine, serine, arginine, lysine, histidine, salts of any of these (particularly, alkali metal, alkaline earth metal, or zinc salts), or combinations of two or more thereof. In at least some embodiments, the amino acid compounds in the composition consist essentially of or consist of amino acids selected from glycine, proline, methionine, serine, arginine, lysine, histidine, salts of any of these (particularly, alkali metal, alkaline earth metal, or zinc salts), or combinations of two or more thereof.

[0033] In some embodiments, the amino acid(s) useful in the treatment compositions may comprise, consist essentially of, or consist of glycine and / or its salts. In other embodiments, the amino acid(s) useful in the treatment compositions may comprise, consist essentially of, or consist of arginine and / or its salts. In other embodiments, the amino acid(s) useful in the treatment compositions may comprise, consist essentially of, or consist of proline and / or its salts. In still other embodiments, the amino acid(s) useful in the treatment compositions may comprise, consist essentially of, or consist of methionine and / or its salts.In other embodiments, the amino acid(s) useful in the treatment compositions may comprise, consist essentially of, or consist of serine and / or its salts. In still other embodiments, the amino acid(s) useful in the treatment compositions may comprise, consist essentially of, or consist of arginine and / or its salts. In still other embodiments, the amino acid(s) useful in the treatment compositions may comprise, consist essentially of, or consist of histidine and / or its salts. In still other embodiments, the amino acid(s) useful in the treatment compositions may comprise, consist essentially of, or consist of lysine and / or its salts.In yet other embodiments, the amino acid(s) useful in the compositions may comprise, consist essentially of, or consist of basic amino acids and / or their salts.

[0034] In various embodiments, the total amount of amino acids may range from about 0.1% to about 15%, such as from about 0.1% to about 12%, from about 0.1% to about 10%, from about 0.1% to about 9%, from about 0.1% to about 8%, from about 0.1% to about 7%, from about 0.1% to about 6%, from about 0.1% to about 5.5%, from about 0.1% to about 5%, from about 0.1% to about 4.5%, from about 0.1% to about 4%, from about 0.1% to about 3.5%, from about 0.1% to about 3%, from about 0.1% to about 2.5%, from about 0.1% to about 2%, from about 0.1% to about 1.5%, from about 0.1% to about 1%, from about 0.5% to about 15%, from about 0.5% to about 12%, from about 0.5% to about 10%, from about 0.5% to about 9%, from about 0.5% to about 8%, from about 0.5% to about 7%, from about 0.5% to about 6%, from about 0.5% to about 5.5%, from about 0.5% to about 5%, from about 0.5% to about 4.5%, from about 0.5% to about 4%, from about 0,5% to about 3.5%, from about 0.5% to about 3%, from about 0.5% to about 2.5%, from about 0.5% to about 2%, from about 0.5% to about 1.5%, from about 0.5% to about 1%, from about 1% to about 15%, from about 1% to about 12%, from about 1% to about 10%, from about 1% to about 9%, from about 1% to about 8%, from about 1% to about 7%, from about 1% to about 6%, from about 1% to about 5.5%, from about 1% to about 5%, from about 1% to about 4.5%, from about 1% to about 4%, from about 1% to about 3.5%, from about 1% to about 3%, from about 1% to about 2.5 %, from about 1% to about 2%, from about 1% to about 1.5%, from about 1.5% to about 15%, from about 1.5% to about 12%, from about 1.5% to about 10%, from about 1.5% to about 9%, from about 1.5% to about 8%, from about 1.5% to about 7%, from about 1.5% to about 6%, from about 1.5% to about 5.5%, from about 1.5% to about 5%, from about 1.5% to about 4.5%, from about 1,5% to about 4%, from about 1.5% to about 3.5%, from about 1.5% to about 3%, from about 1.5% to about 2.5%, from about 1.5% to about 2%, from about 2% to about 15%, from about 2% to about 12%, from about 2% to about 10%, from about 2% to about 9%, from about 2% to about 8%, from about 2% to about 7%, from about 2% to about 6%, from about 2% to about 5.5%, from about 2% to about 5%, from about 2% to about 4.5%, from about 2% to about 4%, from about 2% to about 3.5%, from about 2% to about 3%, from about 2% to about 2.5%, from about 2.5% to about 15%, from about 2.5% to about 12%, from about 2.5% to about 10%, from about 2.5% to about 9%, from about 2.5% to about 8%, from about 2.5% to about 7%, from about 2.5% to about 6%, from about 2.5% to about 5.5%, from about 2.5% to about 5%, from about 2.5% to about 4.5%, from about 2.5% to about 4%, from about 2.5% to about 3.5%, from about 2.5% to about 3%,from about 3% to about 15%, from about 3% to about 12%, from about 3% to about 10%, from about 3% to , about 9%, from about 3% to about 8%, from about 3% to about 7%, from about 3% to about 6%, from about 3% to about 5.5%, from about 3% to about 5%, from about 3% to about 4.5%, from about 3% to about 4%, from about 3% to about 3.5%, from about 3.5% to about 15%, from about 3.5% to about 12%, from about 3.5% to about 10%, from about 3.5% to about 9%, from about 3.5% to about 8%, from about 3.5% to about 7%, from about 3.5% to about 6%, from about 3.5% to about 5.5%, from about 3.5% to about 5%, from about 3.5% to about 4.5%, from about 3.5% to about 4%, from about 4% to about 15%, from about 4% to about 12%, from about 4% to about 10%, from about 4% to about 9%, from about 4% to about 8%, from about 4% to about 7%, from about 4% to about 6%, from about 4% to about 5.5%, from about 4% to about 5%, from about 4% to about 4.5%, from about 4.5% to about 15%, from about 4.5% to about 12%, from about 4.5% to about 10%,from about 4.5% to about 9%, from about 4.5% to about 8%, from about 4.5% to about 7%, from about 4.5% to about 6%, from about 4.5% to about 5.5%, or from about 4.5% to about 5% by weight, based on the total weight of the composition.

[0035] In a preferred embodiment, the treatment compositions comprise arginine and / or a salt thereof. In another preferred embodiment, where more than one amino acid is present, arginine is present in the treatment composition in an amount greater than the combined amounts of the other amino acid(s) present, for example, arginine comprises more than about 50%, such as more than about 60%, more than about 70%, more than about 80%, more than about 90%, more than about 95%, more than about 98%, or more than about 99% of all amino acids present in the composition. In a more preferred embodiment, arginine is the only basic amino acid in the treatment composition.

[0036] In various preferred embodiments, the treatment composition comprises arginine in an amount ranging from about 1% to about 10%, such as from about 2.5% to about 7.5%, preferably from about 3% to about 7%, more preferably from about 3.5% to about 6.5%, more preferably from about 3.75% to about 6.25%, more preferably from about 4% to about 6%, more preferably from about 4.25% to about 5.75%, more preferably from about 4.5% to about 5.5%, even more preferably from about 4.75% to about 5.25%, and most preferably from about 4.8% to about 5.2%, or may be present in an amount of about 4.5%, about 4.6%, about 4.7%, about 4.8%, of about 4.9%, about 5.0%, about 5.1%, about 5.2%, about 5.3%, about 5.4% or about 5.5% by weight, based on the total weight of the composition,including all ranges and subranges using any previous values ​​as upper and lower limits.

[0037] In another preferred embodiment, the compositions according to the disclosure comprise serine and / or a salt thereof. If present, the amount of serine may range from about 0.01% to about 2%, such as from about 0.01% to about 1.5%, from about 0.01% to about 1%, from about 0.01% to about 0.5%, from about 0.01% to about 0.4%, from about 0.01% to about 0.3%, from about 0.01% to about 0.2%, from about 0.01% to about 0.1%, from about 0.05% to about 2%, from about 0.05% to about 1.5%, from about 0.05% to about 1%, from about 0.05% to about 0.5%, from about 0.05% to about 0.4%, from about 0.05% to about 0.3%, from about 0.05% to about 0.2%, from about 0.05% to about 0.1%, from about 0.1% to about 2%, from about 0.1% to about 1.5%, from about 0.1% to about 1% or from about 0.1% to about 0.5% by weight, based on the total weight of the composition.For example, in certain preferred embodiments, the treatment compositions may comprise serine in an amount ranging from about 0.05% to about 1.5%, preferably from about 0.1% to about 1%, more preferably from about 0.25% to about 0.75%, and most preferably from about 0.4% to about 0.6%, such as about 0.1%, about 0.25%, about 0.5%, about 0.75%, or about 1% by weight, based on the total weight of the composition, including all ranges and sub-ranges using any of the foregoing values ​​as upper and lower limits.

[0038] In some embodiments, it may be advantageous to select at least one basic amino acid and at least one additional amino acid selected from acidic and / or neutral amino acids. For example, in preferred embodiments, it may be advantageous to include at least one basic amino acid and serine in the compositions according to the disclosure, and to select total amounts of basic amino acids and serine such that the treatment composition has a weight ratio of the total amount of basic amino acids to the total amount of serine that is greater than about 2, such as greater than about 3, greater than about 4, greater than about 5, or greater than about 6.For example, the treatment composition may have a weight ratio of total basic amino acids to total serine of from about 2 to about 15, such as from about 4 to about 14, from about 6 to about 13, from about 8 to about 12, or from about 9 to about 11. In other examples, the weight ratio of total basic amino acids to serine may be about 8, about 9, about 10, about 11, or about 12. In some preferred embodiments, the treatment composition comprises serine and has a weight ratio of total basic amino acids to serine of from about 2 to about 15, preferably from about 8 to about 12, more preferably from about 9 to about 11, or from about 8, about 9, about 10, about 11, or about 12, including . all ranges and subranges using any previous values ​​as upper and lower limits.

[0039] In still further preferred embodiments, the treatment compositions comprise serine and arginine, and have a weight ratio of arginine to serine ranging from about 2 to about 15, preferably from about 8 to about 12, more preferably from about 9 to about 11, or is about 8, about 9, about 10, about 11, or about 12, including all ranges and sub-ranges using any of the foregoing values ​​as upper and lower limits. Osmolytes

[0040] Osmolytes are molecules, typically of lower molecular weight, used by cells to maintain cell volume, regulate osmotic pressure and maintain cellular homeostasis, for example in response to environmental stressors. Organic osmolytes include aminocarboxylic acids, aminosulfonic acids, their salts and derivatives, carbohydrates such as sugars and sugar alcohols (polyols), polyamines, betaines, methylsulfonium compounds (e.g., dimethylsulfoniopropionate) and urea. For the purposes of this disclosure, "osmolytes" include aminocarboxylic acid derivatives, aminosulfonic acid derivatives, and salts of the derivatives (collectively referred to herein as "amino acid derivatives"), but do not include the aminocarboxylic acids, aminosulfonic acids, or their salts that are described above, and do not include polyols.

[0041] The treatment compositions of the disclosure comprise one or more osmolytes, preferably one or more organic osmolytes. In some embodiments, the treatment compositions comprise more than one osmolyte. While not wishing to be theoretical, it is believed that the use of osmolytes of the disclosure allows treated hair to maintain a moisture balance, thereby reducing potential damage to the hair, or to restore a moisture balance to already damaged hair, thereby allowing the treated hair to regain reduced strength and / or elasticity associated with healthy hair.

[0042] In preferred embodiments, the useful osmolytes are chosen from carbohydrate sugars, polyamines, amino acid derivatives such as betaines, and more preferably are chosen from the compounds of formula (II) or their salts:

[0043] (Rl)(R2)(R3)m-A+-CR4R5-(X)nY (II)

[0044] in which:

[0045] - RI, R2 and R3 are independently chosen from C1-C4 alkyl groups, preferably C1-C2 alkyl groups, more preferably methyl;

[0046] - A is N or S;

[0047] - m and n are independently 0 or 1;

[0048] - X is a divalent alkyl group (= an alkylene group), linear or branched, saturated or unsaturated, having 1 to 6 carbon atoms, preferably 1 to 4 carbon atoms, optionally substituted with one or more groups selected from hydroxyl (-OH) or amino (-NH2); and

[0049] - Y is -COO- or -OSO3-;

[0050] provided that:

[0051] • when A is S, then m = 0 and R4 and R5 are chosen independently from a hydrogen atom or a saturated, unsaturated, linear, branched and / or cyclic (C1-C10) hydrocarbon chain (including aromatic and polycyclic chains), preferably (C1-C6), more preferably (C1-C4); optionally interrupted by one or more heteroatoms or groups selected from -S-, -N=, -NH- or -C(NH)- and / or optionally substituted with one or more groups selected from hydroxyl (-OH), amino (-NH2), -SH, -COOH, or -CONH2;

[0052] • when A is N and m = 0, R4 represents a hydrogen atom or an alkyl (in C1-C8) saturated, linear or branched, preferably a (C1-C4) alkyl group; and R5 forms, with the nitrogen atom, a saturated heterocycle comprising from 5 to 8 ring members, preferably from 5 to 6 ring members, this ring possibly being substituted with one or more groups chosen from a hydroxyl or an (C1-C4) alkyl; and

[0053] • when A is N and m = 1, then R4 and R5 are chosen independently from a hydrogen atom or a saturated, unsaturated, linear, branched and / or cyclic (C1-C10) hydrocarbon chain (including aromatic and polycyclic chains), preferably (C1-C6), more preferably (C1-C4); optionally interrupted by one or more heteroatoms or groups selected from -S-, -N=, -NH- or -C(NH)- and / or optionally substituted with one or more groups selected from hydroxyl (-OH), amino (-NH2), -SH, -COOH or -CONH2.

[0054] Useful and non-limiting polyamine compounds may comprise primary and / or secondary and / or tertiary and / or quaternary amine functional groups. For example, polyamines that may be selected include diamines, triamines, tetramines, pentamines, and polymeric polyamines or polyimines, such as, for example, hexamethylenediamine, diethylenetetramine, diethylenetriamine, polyethyleneimine (PEI), polyvinylamine, polyetheramine, polylysine, ethylenediamine, 1,3-diaminopropane, cadaverine, spermidine, spermine, putrescine, tetraethylmethylenediamine, triethylenetetramine, or combinations of two or more thereof. In some embodiments, the useful polyamines are selected from putrescine, spermidine and / or spermine.

[0055] Useful and non-limiting examples of betaines include glycine betaine, valine betaine, alanine betaine, proline betaine, hydroxyproline betaine, etc. Salts of betaines may also be used and are expressly included in the term "betaine" unless otherwise expressly indicated. In particularly preferred embodiments, the betaines are selected from those corresponding to formula (II). Examples of useful compounds of formula (II) include the compounds shown in Figures 1A and 1B. As shown in [Fig. 1A], in some embodiments, the compounds of formula (II) are in zwitterionic form, and as shown in [Fig. 1B], in some embodiments, the compounds of formula (II) have a corresponding counterion, X.The counterion is not limited and may be any suitable counterion, e.g., a chloride ion, a bromide ion, an iodide ion, a sulfate anion, a sulfonate anion, a methyl sulfate anion, a phosphate anion, a nitrate anion, etc. Thus, as used herein, a "compound of formula (II)" expressly includes both the ionic form of the compound as well as the salt forms, whether or not specified.

[0056] As shown in Figures 1A and 1B, examples of useful compounds of formula (II) include betaine and betaine derivatives (referred to herein as "betaines"), for example, valine betaine, glutamic acid betaine, glutamine betaine, trimethyllysine, glycine betaine (trimethylglycine), histidine betaine, N-methylhistidine betaine, alanine betaine, beta-alanine betaine, choline sulfate, pipecolic acid betaine, proline betaine, hydroxyproline betaine, tyrosine betaine, phenylalanine betaine, tryptophan betaine, leucine betaine, isoleucine betaine and / or dimethylsulfoniopropionate. In a preferred embodiment, the osmolyte is glycine betaine (trimethylglycine), alone or in combination with one or more additional osmolytes, for example one or more additional compounds of formula (II).

[0057] In certain preferred embodiments, the treatment compositions that can be used according to the disclosure comprise at least one compound of formula (II). In additional preferred embodiments, the compositions according to the disclosure comprise one or more compounds of formula (II), i.e., a zwitterionic amino acid derivative bearing a quaternary ammonium group and comprising in total from 1 to 12 carbon atoms, such as from 2 to 10 carbon atoms, or from 3 to 8 carbon atoms.

[0058] In certain preferred embodiments, the treatment compositions comprise at least one compound of formula (II) wherein RI = R2 = methyl; A is N; and / or Y is COO-. In certain other preferred embodiments, the treatment compositions comprise at least one compound of formula (II) wherein R3 is methyl. In other preferred embodiments, the treatment compositions comprise at least one compound of formula (II) wherein X is a divalent, linear or branched, preferably saturated alkyl group having from 1 to 6 carbon atoms, preferably from 1 to 4 carbon atoms, optionally substituted with a group selected from hydroxyl or amino. In still other preferred embodiments, the treatment compositions comprise at least one compound of formula (II) wherein X is a divalent, linear or branched, preferably saturated alkyl group having from 1 to 6 carbon atoms, preferably from 1 to 4 carbon atoms, more preferably from 1 to 2 carbon atoms (unsubstituted), such as methylene or ethylene.In other preferred embodiments, the treatment compositions comprise at least one compound of formula (II) wherein R4 and R5, which may be the same or different, are selected from a hydrogen atom, a saturated, linear or branched (C1-C10) alkyl group, preferably a (C1-C6) alkyl, more preferably a (C1-C4) alkyl; a phenyl group; a benzyl group; an alkyl group substituted with a cyclic group (saturated or unsaturated, mono- or bi-cyclic); a cyclic group (saturated or unsaturated, mono- or bi-cyclic) substituted with an alkyl group; all these groups being optionally interrupted by one or more heteroatoms or groups selected from -S-, -N=, -NH-, or -C(NH)- and / or optionally substituted with one or more groups selected from a hydroxyl. (-OH), amino (-NH2), -SH, -COOH, -CONH2; more preferably where R4 is hydrogen and / or where R5 is hydrogen or saturated, straight or branched (C1-C6) alkyl, more preferably (C1-C4) alkyl; optionally substituted with a group selected from hydroxyl (-OH), amino (-NH2), -COOH or -CONH2. In certain preferred embodiments, when A is N and m = 0, R5 forms, together with the nitrogen atom, a saturated heterocycle comprising from 5 to 8 ring members, preferably from 5 to 6 ring members, optionally substituted with a hydroxy group. In more preferred embodiments, RI = R2 = methyl, A is N, Y is COO-, and X (if present) is a divalent alkyl group which may be straight or branched, saturated or unsaturated, having from 1 to 6 carbon atoms, preferably from 1 to 4 carbon atoms, more preferably from 1 to 2 carbon atoms.

[0059] In a preferred embodiment, the treatment composition comprises at least one compound of formula (II) in which RI = R2 = R3 = methyl; A is N; Y is COO-; X is a divalent, linear or branched, preferably saturated alkyl group having from 1 to 4 carbon atoms, optionally substituted with a group selected from a hydroxyl or an amino, more preferably from 1 to 2 carbon atoms (unsubstituted), such as methylene or ethylene; R4 is hydrogen; and R5 forms, with the nitrogen atom, a saturated heterocycle comprising from 5 to 8 ring members, preferably from 5 to 6 ring members, optionally substituted with a hydroxy group.

[0060] In preferred embodiments, the osmolyte in the treatment composition comprises, consists essentially of, or consists of one or more of the compounds shown in Figures 1A and 1B. In more preferred embodiments, the compositions according to the disclosure comprise trimethylglycine (interchangeably referred to as glycine betaine), optionally in combination with at least one additional osmolyte, and in particularly preferred embodiments, the osmolyte in the treatment composition comprises, consists essentially of, or consists of glycine betaine optionally with at least one additional compound of formula (II).

[0061] Useful and non-limiting examples of carbohydrate sugars that may be used include C3-C6 monosaccharides, for example, pentoses and / or derivatives thereof, or hexoses and / or derivatives thereof. For example, the sugars may optionally be selected from xylose, arabinose, ribose, 2-deoxy-ribose, ribulose, deoxy-ribulose, arabinose, xylulose, allose, altrose, glucose (including dextrose), glucosamine, mannose, gulose, idose, galactose, talose, sorbose, psicose, fructose, tagatose, or combinations of two or more thereof. In at least some embodiments, the sugars are selected from disaccharides, e.g., sucrose, maltose, lactose, cellobiose, trehalose, dextran, or from polysaccharides, e.g., maltotriose, starch, dextrins, cellulose, glycogen, or combinations of two or more thereof.In some embodiments, the sugars are preferably selected from trehalose, glucose, sucrose, fructose, fructans, or combinations of two or more thereof.

[0062] In various embodiments, the total amount of osmolytes present in the treatment composition may range from about 0.01% to about 15%, such as, for example, from about 0.1% to about 10%, from about 0.1% to about 9%, from about 0.1% to about 8%, from about 0.1% to about 7%, from about 0.1% to about 6%, from about 0.1% to about 5%, from about 0.1% to about 4%, from about 0.1% to about 3%, from about 0.1% to about 2%, from about 0.1% to about 1%, from about 0.5% to about 10%, from about 0.5% to about 9%, from about 0.5% to about 8%, from about 0.5% to about 7%, from about 0.5% to about about 6%, from about 0.5% to about 5%, from about 0.5% to about 4%, from about 0.5% to about 3%, from about 0.5% to about 2%, from about 0.5% to about 1%, from about 1% to about 10%, from about 1% to about 9%, from about 1% to about 8%, from about 1% to about 7%, from about 1% to about 6%, from about 1% to about 5%, from about 1% to about 4%, from about 1% to about 3%, from about 1% to about 2%, from about 1.5% to about 10%, from about 1.5% to about 9%, from about 1.5% to about 8%, from about 1.5% to about 7%, from about 1.5% to about 6%, from about 1.5% to about 5%, from about 1.5% to about 4%, from about 1.5% to about 3%, from about 1.5% to about 2%, from about 2% to about 10%, from about 2% to about 9%, from about 2% to about 8%, from about 2% to about 7%, from about 2% to about 6%, from about 2% to about 5%, from about 2% to about 4%, from about 2% to about 3%, from about 2.25% to about 10%, from about 2.25% to about 9%, from about 2.25% to about 8%, from about 2.25% to about 7%, from about 2.25% to about 6%, from about 2.25% to about 5%, from about 2.25% to about 4%, from about 2.25% to about 3%, from about 2.5% to about 10%, from about 2.5% to about 9%, from about 2,5% to about 8%, from about 2.5% to about 7%, from about 2.5% to about 6%, from about 2.5% to about 5%, from about 2.5% to about 4%, from about 2.5% to about 3% by weight, based on the total weight of the composition. For example, the total amount of osmolytes present in the treatment composition may be about 2.0%, about 2.1%, about 2.2%, about 2.3%, about 2.4%, about 2.5%, about 2.6%, about 2.7%, about 2.8%, about 2.9% or about 3.0% by weight, based on the total weight of the composition, including all ranges and sub-ranges using any of the foregoing values ​​as upper and lower limits.

[0063] In preferred embodiments, the treatment composition comprises at least one betaine, and the total amount of betaines ranges from about 0.5% to about 5%, for example from about 1% to about 5%, preferably from about 1.25% to about 4%, more preferably from about 1.5% to about 3.5%, more preferably from about 2% to about 3% or from about 2% to about 2.5%, more preferably from 2.25% to about 2.75%, and most preferably from about 2.3% to about 2.6%, or may be from about 2.0%, from about 2.1%, from about 2.2%, from about 2.3%, from about 2.4%, from about 2.5%, from about 2.6%, from about 2.7%, from about 2.8%, from about 2.9%, or about 3.0% by weight, based on the total weight of the composition, including all ranges and sub-ranges using any of the preceding values ​​as upper and lower limits.

[0064] In a particularly preferred embodiment, the treatment composition comprises glycine betaine in an amount ranging from about 0.5% to about 5%, for example from about 1% to about 5%, preferably from about 1.25% to about 4%, more preferably from about 1.5% to about 3.5%, more preferably from about 2% to about 3% or from about 2% to about 2.5%, more preferably from about 2.25% to about 2.75%, and most preferably from about 2.3% to about 2.6%, or the glycine betaine may be present in an amount of about 2.0%, about 2.1%, about 2.2%, about 2.3%, about 2.4%, about 2.5%, about 2.6%, about 2.7%, about 2.8%, about 2.9%, or about 3.0% by weight, based on the total weight of the composition, including all ranges and sub-ranges using any of the preceding values ​​as upper and lower limits.

[0065] In some embodiments, it may be advantageous to select amounts of amino acids and osmolytes so as to provide a weight ratio of the total amount of amino acid(s) and their salts in the treatment composition to the total amount of osmolytes in the treatment composition that is greater than about 0.1, for example, greater than about 0.2, greater than about 0.5, greater than about 1, greater than about 1.25, greater than about 1.5, greater than about 1.75, or greater than about 2. In various embodiments, the weight ratio of the total amount of amino acid(s) and their salts to the total amount of osmolytes may range from about 0.1 to about 10, such as from about 0.2 to about 8, from about 0.5 to about 6, from about 1 to about 5, from about 1.2 to about 4, or from about 1.5 to about 3.5.In other embodiments, the weight ratio of the total amount of amino acid(s) and their salts to the total amount of osmolytes may range from greater than 1 to about 4, such as from about 1.25 to about 3.5, from about 1.5 to about 3, from about 1.75 to about 2.5, from about 1.75 to about 2.25, or from about 1.8 to about 2.2. For example, the weight ratio of the total amount of amino acid(s) in the treatment composition to the total amount of osmolytes in the treatment composition may be about 1.1, about 1.2, about 1.3, about 1.4, about 1.5, about 1.6, about 1.7, about 1.8, about 1.9, about 2, about 2.1, about 2.2, about 2.3, about 2.4, or about 2.5, including all ranges and subranges using any of the foregoing values ​​as upper and lower limits.

[0066] In some embodiments, the treatment compositions comprise a total amount of amino acids selected from compounds of formula (I), and a total amount of osmolytes selected from compounds of formula (II) such that a weight ratio of compounds of formula (I):compounds of formula (II) is greater than about 0.5, greater than about 0.75, or greater than about 1, for example, greater than about 1.25, greater than about 1.5, greater than about 1.75, or greater than about 2. In some embodiments, the weight ratio of compounds of formula (I):compounds of formula (II) in the composition may range from about 0.5 to about 6, for example, from about 1 to about 4, from about 1.25 to about 3.5, from about 1.5 to about 3, from about 1.75 to about 2.5, from about 1.75 to about 2.25, or from about 1.8 to about 2.2. For example, the weight ratio of compounds of formula (I):compounds of formula (II) in the composition may be about 0.5, about 0.6, about 0.7, about 0.8, about 0.9, about 1, about 1.1, about 1.2, about 1.3, about 1.4, about 1.5, about 1.6, about 1.7, about 1.8, about 1.9, about 2, about 2.1, about 2.2, about 2.3, about 2.4 or about 2.5, including all ranges and subranges using any of the preceding values ​​as upper and lower limits.

[0067] In a particularly preferred embodiment, the treatment composition comprises arginine and glycine betaine and has a weight ratio of arginine to glycine betaine greater than 1, for example, greater than about 1.25, greater than about 1.5, greater than about 1.75, or greater than about 2, for example, from greater than 1 to about 4, preferably from about 1.5 to about 3, more preferably from about 1.75 to about 2.5, and most preferably from about 1.75 to about 2.25.In another particularly preferred embodiment, the treatment composition comprises arginine, serine and glycine betaine and has a weight ratio of the total amount of [arginine + serine] to glycine betaine greater than 1, for example greater than about 1.25, greater than about 1.5, greater than about 1.75, or greater than about 2, for example from greater than 1 to about 4, preferably from about 1.5 to about 3, more preferably from about 1.75 to about 2.5, and most preferably from about 1.75 to about 2.25. Carboxylic acids

[0068] The treatment compositions that can be used in the methods according to the disclosure include at least one carboxylic acid. Optionally, the treatment compositions can include at least two carboxylic acids, at least three carboxylic acids, etc. According to various embodiments of the disclosure, useful carboxylic acids include organic compounds that include, for example, one (mono-), two (di-), three (tri-) or more acid functional groups and at least one carbon atom.

[0069] The carboxylic acids that may be used may optionally have a molecular weight of less than about 500 g / mol, less than about 400 g / mol, less than about 300 g / mol, or less than about 200 g / mol. In preferred embodiments, the carboxylic acids have a molecular weight of less than about 300 g / mol, or less than about 200 g / mol.

[0070] Salts of carboxylic acids may also be used and are expressly included in the term "carboxylic acid" unless otherwise indicated. Salts include salts with organic or inorganic bases, for example, alkali metal salts, such as lithium, sodium, or potassium salts; alkaline earth metal salts, such as magnesium or calcium salts; and salts of zinc. Alkali metal or alkaline earth metal salts are preferred in certain embodiments, and in particular sodium salts.

[0071] In preferred embodiments, the carboxylic acids comprise from 2 to 20 carbon atoms, such as from 2 to 18 carbon atoms, from 3 to 16 carbon atoms, or from 3 to 14 carbon atoms. In some preferred embodiments, the treatment compositions comprise one or more hydroxylated (poly)carboxylic acids comprising from 2 to 10 carbon atoms, such as from 2 to 8 carbon atoms, or from 3 to 6 carbon atoms, and may be saturated or unsaturated, and linear or branched, and / or a salt thereof. These (poly)acids are different from the amino acid compounds described above. Useful (poly)acids comprise at least one -COOH group (in acid or salified form); they can thus comprise a single -COOH group (monoacid) or can comprise more than one -COOH group, for example two (in acid or salified form), or two or three -COOH groups (in acid or salified form) (polyacids).Useful (poly)acids also comprise at least one -OH group, such as one to three or two to three -OH groups, for example, one, two, or three -OH groups. Preferably, the (poly)acids comprise a total of 2 to 8 or 3 to 6 carbon atoms, and two to three -OH groups, and their hydrocarbon chain is saturated or unsaturated, linear or branched, and preferably saturated and linear. In certain preferred embodiments, the hydroxylated (poly)carboxylic acids and / or their salts comprise a total of 3 to 6 carbon atoms, one to three -OH groups, and two to three -COOH groups (in acid or salified form). Unless otherwise indicated, as used herein, the term "(poly)acid" includes both monobasic and polybasic acids.

[0072] Non-limiting examples of monocarboxylic acids that may be selected include formic acid, acetic acid, propionic acid, butyric acid, valeric acid, caproic acid, enanthic acid, caprylic acid, lactic acid, their salts, or combinations of two or more thereof. In some embodiments, the carboxylic acid may comprise, consist essentially of, or consist of lactic acid and / or a salt thereof.

[0073] Non-limiting examples of dicarboxylic acids that may be selected include oxalic acid, malonic acid, malic acid, glutaric acid, citraconic acid, succinic acid, adipic acid, tartaric acid, fumaric acid, maleic acid, their salts, or combinations of two or more thereof. In some embodiments, the treatment compositions may include oxalic acid, malonic acid, malic acid, maleic acid, their salts, or combinations of two or more thereof.

[0074] Non-limiting examples of tricarboxylic acids include citric acid, isocitric acid, aconitic acid, propane-1,2,3-tricarboxylic acid, their salts, or combinations of two or more thereof. In some embodiments, the carboxylic acid may comprise, consist essentially of, or consist of citric acid and / or a salt thereof.

[0075] In some embodiments, the carboxylic acid(s) may be selected from oxalic acid, malonic acid, glutaric acid, succinic acid, adipic acid, glycolic acid, citric acid, tartaric acid, malic acid, maleic acid, lactic acid, their salts, or combinations of two or more thereof. In particularly preferred embodiments, the carboxylic acids are selected from α-hydroxy acids and their salts, and in particular from lactic acid, glycolic acid, tartaric acid or citric acid, and their salts, in particular alkali metal or alkaline earth metal salts.In some embodiments, it may be particularly advantageous to select citric acid, lactic acid and / or tartaric acid and / or their salts, in particular alkali metal or alkaline earth metal salts, such as sodium citrate and / or sodium tartrate; preferably citric acid and / or its salts, in particular alkali metal or alkaline earth metal salts, such as sodium citrate.

[0076] The total amount of carboxylic acid(s) may range from about 0.5% to about 20% by weight, relative to the total weight of the composition. For example, in some embodiments, the total amount of carboxylic acids ranges from about 1% to about 15%, including about 1% to about 12%, about 1% to about 10%, about 1% to about 9%, about 1% to about 8%, about 1% to about 7%, about 1% to about 6%, about 1% to about 5.5%, about 1% to about 5%, about 1% to about 4.5%, about 1% to about 4%, about 1% to about 3.5%, about 1% to about 3%, about 1% to about 2.5%, about 1% to about 2%, about 1% to about 1.5%, about 1.5% to about 15%, about 1.5% to about 12%, about 1.5% to about 10%, from about 1.5% to about 9%, from about 1.5% to about 8%, from about 1.5% to about 7%, from about 1.5% to about 6%, from about 1.5% to about 5.5%, from about 1,5% to about 5%, from about 1.5% to about 4.5%, from about 1.5% to about 4%, from about 1.5% to about 3.5%, from about 1.5% to about 3%, from about 1.5% to about 2.5%, from about 1.5% to about 2%, from about 2% to about 15%, from about 2% to about 12%, from about 2% to about 10%, from about 2% to about 9%, from about 2% to about 8%, from about 2% to about 7%, from about 2% to about 6%, from about 2% to about 5.5%, from about 2% to about 5%, from about 2% to about 4.5%, from about 2% to about 4%, from about 2% to about 3.5%, from about 2% to about 3 %, from about 2% to about 2.5%, from about 2.5% to about 15%, from about 2.5% to about 12%, from about 2.5%, % to about 10%, from about 2.5% to about 9%, from about 2.5% to about 8%, from about 2.5% to about 7%, from about 2.5% to about 6%, from about 2.5% to about 5.5%, from about 2.5% to about 5%, from about 2.5% to about 4.5%, from about 2.5% to about 4%, from about 2.5% to about 3.5%, from about 2.5% to about 3%, from about 3% to about 15%, from about 3% to about 12%, from about 3% to about 10%, from about 3% to about 9%, from about 3% to about 8%, from about 3% to about 7%, from about 3% to about 6%, from about 3% to about 5.5%, from about 3% to about 5%, from about 3% to about 4.5%, from about 3% to about 4%, from about 3% to about 3.5%, from about 3.5% to about 15%, from about 3.5% to about 12%, from about 3.5% to about 10%, from about 3.5% to about 9%, from about 3.5% to about 8%, from about 3.5% to about 7%, from about 3.5% to about 6%, from about 3.5% to about 5.5%, from about 3.5% to about 5%, from about 3,5% to about 4.5%, from about 3.5% to about 4%, from about 4% to about 15%, from about 4% to about 12%, from about 4% to about 10%, from about 4% to about 9%, from about 4% to about 8%, from about 4% to about 7%, from about 4% to about 6%, from about 4% to about 5.5%, from about 4% to about 5%, from about 4% to about 4.5%, from about 4.5% to about 15%, from about 4.5% to about 12%, from about 4.5% to about 10%, from about 4.5% to about 9%, from about 4.5% to about 8%, from about 4.5% to about 7%, from about 4.5% to about 6%, from about 4.5% to about 5.5%, from about 4.5% to about 5%, from about 5% to about 15%, from about 5% to about 12%, from about 5% to about 10%, from about 5% to about 9%, from about 5% to about 8%, from about 5% to about 7%, from about 5% to about 6.5%, from about 5% to about 6%, from about 5% to about 5.5%, from about 5.5% to about 15%, from about 5.5% to about 12%, from about 5.5% to about 10%,from about 5.5% to about 9%, from about 5.5% to about 8%, from about 5.5% to about 7%, from about 5.5% to about 6.5%, from about 5.5% to about 6%, from about 6% to about 15%, from about 6% to about 12%, from about 6% to about 10%, from about 6% to about 9%, from about 6% to about 8%, from about 6% to about 7%, or from about 6% to about 6.5% by weight, based on the total weight of the composition.

[0077] In preferred embodiments, the total amount of carboxylic acid(s) ranges from about 0.5% to about 20%, such as from about 2% to about 15%, from about 4% to about 10%, from about 4.5% to about 8%, from about 5% to about 7%, from about 5.5% to about 6.5%, from about 5.7% to about 6.3%, or from about 5.8% to about 6.2% by weight, based on the total weight of the composition. For example, in some preferred embodiments, the treatment composition comprises at least one carboxylic acid selected from citric acid, lactic acid, tartaric acid, salts thereof, or combinations thereof, and has a total amount of carboxylic acids and salts ranging from about 0.5% to about 20%, such as from about 2% to about 15%, from about 4% to about 10%, preferably from about 4.5% to about 8%, more preferably from about 5% to about 7%, more preferably from about 5.5% to about 6.5%, more preferably still from about 5.7% to about 6.3%, and most preferably from about 5.8% to about 6.2% by weight, based on the total weight of the composition.

[0078] It may be advantageous in some embodiments to select amounts of amino acids and carboxylic acids such that the treatment composition has a weight ratio of total amino acids to total carboxylic acids greater than about 0.75. For example, in various embodiments, the treatment composition has a weight ratio of total amino acids to total carboxylic acids greater than about 0.8, such as greater than about 0.9, greater than about 1, greater than about 1.1, greater than about 1.2, greater than about 1.3, greater than about 1.4, or greater than about 1.5.In some embodiments, the treatment composition has a weight ratio of total amino acids to total carboxylic acids ranging from about 0.75 to about 2, for example, from about 0.8 to about 1.5, from about 0.8 to about 1.35, or from about 0.8 to about 1.2. In certain preferred embodiments, the treatment composition comprises arginine and at least one carboxylic acid selected from citric acid, lactic acid, tartaric acid, their salts, or combinations thereof, and has a weight ratio of the total amount of amino acids and their salts to the total amount of carboxylic acids and their salts ranging from about 0.75 to about 2, preferably from about 0.8 to about 1.5, more preferably from about 0.8 to about 1.35, and most preferably from about 0.8 to about 1.2. Solvents

[0079] The treatment compositions that may be used in the methods according to the disclosure comprise at least one solvent. In various embodiments, the solvent may be selected from water, non-aqueous solvents, or a combination thereof.

[0080] In preferred embodiments, the solvent includes water. In some embodiments, the treatment composition comprises from about 50% to about 98% water, by weight, based on the total weight of the composition. In some embodiments, the treatment composition comprises water in an amount ranging from at least 50% by weight to about 95% by weight, such as from about 50% to about 90%, from about 55% to about 90%, from about 60% to about 90% by weight, or from about 60% to about 80% by weight, based on the total weight of the composition.

[0081] In other embodiments, the solvent may include at least one non-aqueous solvent. Non-limiting examples of non-aqueous solvents that may be used include, for example, glycerin, C1-4 alcohols, organic solvents, fatty alcohols, fatty ethers, fatty esters, polyols, glycols, vegetable oils, mineral oils, liposomes, lamellar lipid materials, or combinations thereof.The non-aqueous solvent may be selected from organic solvents, for example monoalcohols and polyols such as ethyl alcohol, isopropyl alcohol, propyl alcohol, benzyl alcohol and phenylethyl alcohol, or glycols or glycol ethers such as, for example, monomethyl-, monoethyl- and monobutyl-ethers of ethylene glycol, propylene glycol or their ethers such as, for example, monomethyl ether of propylene glycol, butylene glycol, hexylene glycol, dipropylene glycol, as well as alkyl ethers of diethylene glycol, for example monoethyl ether or monobutyl ether of diethylene glycol.

[0082] Preferably, the compositions comprise at least one polyol. The polyols may be selected from diols and triols. In other embodiments, the polyols may be selected from C2-C16 polyols, such as C2-C12 polyols, C2-C8 polyols, or C3-C8 polyols. In various embodiments, the polyols that may be used are linear or branched, saturated or unsaturated, and substituted or unsubstituted polyols. Thus, in various embodiments, one or more polyols may be selected from C2-C16, C2-C12, C2-C8 or C3-C8 diols, or C2-C16, C2-C12, C2-C8 or C3-C8 triols, any of which may be linear or branched, saturated or unsaturated, and substituted or unsubstituted.

[0083] By way of non-limiting example, polyols such as isopropyl alcohol, propyl alcohol, benzyl alcohol and phenylethyl alcohol, or glycols or glycol ethers such as, for example, monomethyl-, monoethyl- and monobutyl-ethers of ethylene glycol, propylene glycol or their ethers such as, for example, monomethyl ether of propylene glycol, butylene glycol, hexylene glycol, dipropylene glycol, as well as alkyl ethers of diethylene glycol, for example monoethyl ether or monobutyl ether of diethylene glycol may be chosen.In some embodiments, the polyols are selected from propanediol, butanediol, pentanediol, hexanediol, heptanediol, octanediol, 1,2,6-hexanetriol, 1,2,4-butanetriol, trimethylolpropane, 2-butene-1,4-diol, 2-ethyl-1,3-hexanediol, 2-methyl-2,4-pentanediol, caprylyl glycol, 1,2-hexanediol, 1,2-pentanediol, 2-ethyl-2-methyl-1,3-propanediol, 3,3-dimethyl-1,2-butanediol, 2,2-diethyl-1,3-propanediol, 2-methyl-2-propyl-1,3-propanediol, 2,4-dimethyl-2,4-pentanediol, 2,5-dimethyl-2,5-hexanediol, 5-hexene-1,2-diol, 2-ethyl-1,3-hexanediol, 4-methyl-1,2-pentanediol, or combinations of two or more thereof. In certain preferred embodiments, the polyols are selected from . among glycols such as ethylene glycol, propylene glycol, butylene glycol, hexylene glycol, pentylene glycol, 1,3-propanediol, diethylene glycol, triethylene glycol, tetraethylene glycol, pentaethylene glycol, dipropylene glycol, caprylyl glycol, glycerin, diglycerin, and combinations of two or more thereof. In a particularly preferred embodiment, the solvent comprises at least one polyol selected from propylene glycol, dipropylene glycol, tripropylene glycol, propanediol, propylene carbonate, PPG-3 methyl ether, dimethylisosorbide, hexylene glycol, ethanol, glycerin, or combinations of two or more thereof.In at least some preferred embodiments, the solvent comprises water and at least one polyol, wherein the polyol(s) comprise(s), consist(s) essentially of, or consist(s) of one or more C2-C16 diols and / or C2-C16 triols, for example, C2-C8 diols and / or C2-C8 triols. In other preferred embodiments, the solvent comprises water and at least one polyol, wherein the polyol(s) comprise(s), consist(s) essentially of, or consist(s) of one or more glycols, for example, propylene glycol and / or dipropylene glycol, and in particularly preferred embodiments, the solvent comprises water and at least one polyol, wherein the polyol(s) comprise(s), consist(s) essentially of, or consist(s) of dipropylene glycol. .

[0084] If present, the total amount of non-aqueous solvents in the treatment composition may range from about 0.1% to about 20%, such as from about 1% to about 20%, from about 1.5% to about 15%, or from about 2% to about 12% by weight, based on the total weight of the composition. In certain preferred embodiments, the solvent comprises water and at least one non-aqueous solvent, preferably selected from polyols.In some embodiments, the treatment composition comprises water and at least one non-aqueous solvent, wherein the total amount of non-aqueous solvents ranges from about 0.5% to about 18%, preferably from about 1% to about 15%, more preferably from about 1.5% to about 12%, more preferably from about 2% to about 11%, and most preferably from about 3% to about 10% by weight, based on the total weight of the composition, and optionally further wherein the non-aqueous solvent comprises at least one solvent selected from propylene glycol, dipropylene glycol, tripropylene glycol, propanediol, propylene carbonate, PPG-3 methyl ether, dimethylisosorbide, hexylene glycol, ethanol, or mixtures of two or more thereof, preferably selected from propylene glycol, dipropylene glycol, or a mixture of two or more of these. Surfactants

[0085] The treatment compositions that may be used in the methods according to the disclosure may optionally comprise at least one surfactant. For example, the treatment compositions may comprise one or more cationic surfactants and / or amphoteric surfactants, and in some embodiments, the compositions may comprise mixtures of surfactants having the same or different ionicities.

[0086] Although the treatment compositions may optionally include one or more anionic surfactants and / or nonionic surfactants, in at least some embodiments, the compositions are free or substantially free of anionic surfactants and / or nonionic surfactants. For example, in some embodiments, the compositions comprise less than about 3%, such as less than about 2.5%, less than about 2%, less than about 1.75%, less than about 1.5%, less than about 1.25%, less than about 1%, less than about 0.75%, less than about 0.5%, less than about 0.25%, less than about 0.2%, less than about 0.1%, less than about 0.05%, less than about 0.01%, or less than about 0.001% of anionic surfactants and / or nonionic surfactants.

[0087] In at least some embodiments, the treatment compositions comprise at least one cationic surfactant. The term "cationic surfactant" refers to a surfactant that is positively charged when contained in the composition(s) according to the disclosure. This surfactant may carry one or more permanent positive charges or may contain one or more cationizable functionalities in the composition according to the disclosure. Non-limiting examples of useful cationic surfactants include brassicamidopropyldimethylamine, behentrimonium chloride, cetrimonium chloride, behenalkonium chloride, benzethonium chloride, cetylpyridinium chloride, behentrimonium chloride, lauralkonium chloride, cetalkonium chloride, cetrimonium bromide, ceethylamine hydrofluoride, chlorallylmethenamine chloride (Quaternium-15), distearyldimonium chloride (Quaternium-5),dodecyldimethylethylbenzylammonium chloride (Quatemium-14), Quatemium-22, Quaternium-26, Quatemium-18 hectorite, dimethylaminoethyl chloride hydrochloride, cysteine ​​hydrochloride, diethanolammonium phosphate POE(10) oleyl ether, diethanolammonium phosphate POE(3) oleyl ether, tallow alkonium chloride, dimethyldioctadecylammoniumbentonite, stearalkonium chloride, domiphene bromide, denatonium benzoate, myristalkonium chloride, laurtrimonium chloride, ethylenediamine dihydrochloride, guanidine hydrochloride, pyridoxine HCl, iofetamine hydrochloride, meglumine hydrochloride, methylbenzethonium chloride, myrtrimonium bromide, oleyltrimonium chloride, polyquatemium-1, , procaine hydrochloride, cocobetaine, stearalkonium bentonite, stearalkonium hectonite, stearyltrihydroxyethylpropylenediamine dihydrofluoride, sulfrimonium chloride, hexadecyltrimethylammonium bromide, stearamidopropyldimethylamine, or combinations thereof. In preferred embodiments, the compositions comprise at least one cationic surfactant selected from brassicamidopropyldimethylamine, behentrimonium chloride, cetrimonium chloride, stearamidopropyldimethylamine, or combinations of two or more thereof.

[0088] If present, the total amount of cationic surfactants may be up to about 10%, such as up to about 9%, up to about 8%, up to about 7%, up to about 6%, up to about 5%, up to about 4%, up to about 3.5%, up to about 3%, up to about 2.5%, up to about 2%, up to about 1.5%, up to about 1%, or up to about 0.5% by weight, based on the total weight of the composition. For example, the total amount of cationic surfactants may be from about 0.001% to about 10%, from about 0.01% to about 8%, from about 0.1% to about 6%, or from about 0.5% to about 4% by weight, based on the total weight of the composition.In at least some preferred embodiments, the treatment compositions comprise at least one cationic surfactant, and have a total amount of cationic surfactants ranging from about 0.25% to about 8%, preferably from about 0.5% to about 7%, more preferably from about 0.75% to about 6%, and most preferably from about 1% to about 5% by weight, based on the total weight of the composition.

[0089] In at least some embodiments, the treatment compositions comprise at least one amphoteric surfactant. Non-limiting examples of useful amphoteric surfactants include secondary and tertiary aliphatic amine derivatives where the aliphatic radical may be a straight or branched chain and one of the aliphatic substituents contains from about 8 to about 18 carbon atoms and one contains an anionic group, such as a carboxy, sulfonate, sulfate, phosphate, or phosphonate.Examples of amphoteric surfactants include sodium cocaminopropionate, sodium cocaminodipropionate, sodium cocoamphoacetate, sodium cocoamphohydroxypropylsulfonate, sodium cocoamphopropionate, sodium cornamphopropionate, sodium lauraminopropionate, sodium lauroamphoacetate, sodium lauroamphohydroxypropylsulfonate, sodium lauroamphopropionate, sodium cornamphopropionate, sodium lauriminodipropionate, ammonium cocaminopropionate, ammonium cocaminodipropionate, ammonium cocoamphoacetate, ammonium cocoamphohydroxypropylsulfonate, ammonium cocoamphopropionate, cornamphopropionate. ammonium, ammonium lauraminopropionate, ammonium lauroamphoacetate, ammonium lauroamphohydroxypropylsulfonate, ammonium lauroamphopropionate, ammonium cornamphopropionate, ammonium lauriminodipropionate, triethanolamine cocaminopropionate, triethanolamine cocaminodipropionate, triethanolamine cocoamphoacetate, triethanolamine cocoamphohydroxypropylsulfonate, triethanolamine cocoamphopropionate, triethanolamine cornamphopropionate, triethanolamine lauraminopropionate, triethanolamine lauroamphoacetate, triethanolamine lauroamphohydroxypropylsulfonate, triethanolamine lauroamphopropionate, triethanolamine cornamphopropionate, triethanolamine lauriminodipropionate, cocoamphodipropionic acid, disodium caproamphodiacetate, disodium caproamphoadipropionate, disodium capryloamphodiacetate, disodium capryloamphodipriopionate,disodium cocoamphocarboxyethylhydroxypropylsulfonate, disodium cocoamphodiacetate, disodium cocoamphodipropionate, disodium dicarboxyethylcocopropylenediamine, disodium laureth-5 carboxyamphodiacetate, disodium lauriminodipropionate, disodium lauroamphodiacetate, disodium lauroamphodipropionate, disodium oleoamphodipropionate, disodium PPG-2-isodecethyl-7 carboxyamphodiacetate, lauraminopropionic acid, lauroamphodipropionic acid, laurylaminopropylglycine and lauryldiethylenediaminoglycine.

[0090] Betaine type surfactants can also be used. For example, cocodimethylcarboxymethyl betaine, lauryldimethylcarboxymethyl betaine, lauryldimethylalphacarboxyethyl betaine, cetyldimethylcarboxymethyl betaine, cetyldimethyl betaine, laurylbis-(2-hydroxyethyl)carboxymethyl betaine, stearylbis-(2-hydroxypropyl)carboxymethyl betaine, oleyldimethylgamma-carboxypropyl betaine, laurylbis-(2-hydroxypropyl)alpha-carboxyethyl betaine, cocodimethylsulfopropyl betaine, stearyldimethylsulfopropyl betaine, lauryldimethylsulfoethyl betaine, laurylbis-(2-hydroxyethyl)sulfopropyl betaine, oleyl betaine or cocamidopropyl betaine may be selected.

[0091] If present, the total amount of amphoteric surfactants may be up to about 10%, such as up to about 9%, up to about 8%, up to about 7%, up to about 6%, up to about 5%, up to about 4%, up to about 3.5%, up to about 3%, up to about 2.5%, up to about 2%, up to about 1.5%, up to about 1%, or up to about 0.5% by weight, based on the total weight of the composition. For example, the total amount of amphoteric surfactants may be from about 0.001% to about 6%, from about 0.01% to about 4%, from about 0.1% to about 3%, or from about 0.5% to about 2% by weight, based on the total weight of the composition. In at least some embodiments, the treatment compositions are free or substantially free of amphoteric surfactants. Fatty compounds

[0092] Optionally, the treatment compositions that may be used in the methods according to the disclosure may include at least one fatty compound. In some embodiments, the at least one fatty compound may be selected from lower alkanes, fatty alcohols, fatty acids, fatty acid esters, fatty alcohol esters, oils such as mineral, vegetable, animal, silicone and non-silicone oils, silicone and non-silicone waxes, or combinations of two or more thereof.

[0093] In some embodiments, the treatment compositions include at least one fatty compound selected from volatile and non-volatile silicone oils, which may optionally be aminofunctionalized. Non-limiting examples of silicone oils that may be used include dimethicone, amodimethicone, cyclomethicone, polysilicone-11, phenyltrimethicone, trimethylsilylamodimethicone, and stearoxytrimethylsilane.For example, the composition may comprise at least one silicone selected from amodimethicone, PEG-7 dimethicone, PEG-8 dimethicone, PEG-9 dimethicone, PEG-10 dimethicone, PEG-12 dimethicone, PEG-14 dimethicone, PEG-17 dimethicone, PEG / PPG-3 / 10 dimethicone, PEG / PPG-4 / 12 dimethicone, PEG / PPG-17 / 18 dimethicone, cetyl PEG / PPG-10 / 1 dimethicone, PEG-8 dimethicone benzoate, PEG-7 dimethicone phosphate, PEG-8 dimethicone phosphate, PEG-10 dimethicone phosphate, or a mixture of two or more thereof. In certain preferred embodiments, the treatment compositions comprise a silicone oil component that comprises, consists essentially of, or consists of dimethicone, amodimethicone, or a mixture thereof.

[0094] As further examples, the silicone oil may be selected from polydimethylsiloxanes (PDMS), polydimethylsiloxanes comprising alkyl or alkoxy groups which are pendant and / or at the end of the silicone chain, which groups each contain from 2 to 24 carbon atoms, or phenylsilicones, such as phenyltrimethicones, phenyldimethicones, phenyl(trimethylsiloxy)diphenylsiloxanes, diphenyldimethicones, diphenyl(methyl-diphenyl)trisiloxanes or (2-phenylethyl)trimethyl-siloxysilicates.

[0095] In some embodiments, the treatment compositions include at least one fatty compound selected from fatty alcohols. In some embodiments, "fatty alcohol" refers to any C5 or higher carbon chain alcohol, such as, for for example, C8 or higher, C10 or higher, or C12 or higher, such as 6 to 30 carbon atoms or 8 to 30 carbon atoms. Fatty alcohols may be alkoxylated or non-alkoxylated, saturated or unsaturated, and linear or branched.

[0096] For example, the fatty alcohols may be selected from arachidyl alcohol, behenyl alcohol, caprylic alcohol, cetearyl alcohol, cetyl alcohol, coconut alcohol, decyl alcohol, hydrogenated tallow alcohol, jojoba alcohol, lauryl alcohol, myristyl alcohol, oleyl alcohol, palm alcohol, palm kernel alcohol, stearyl alcohol, tallow alcohol, tridecyl alcohol, or combinations of two or more thereof. In certain preferred embodiments, the treatment compositions comprise a fatty alcohol component that comprises, consists essentially of, or consists of cetyl alcohol, stearyl alcohol, cetearyl alcohol, or mixtures thereof.

[0097] Useful and non-limiting fatty acids may be straight or branched chain acids and / or may be saturated or unsaturated. Non-limiting examples of fatty acids include dibasic, tribasic, and other multiple acids as well as salts of these fatty acids. For example, the fatty acid may optionally include or be selected from lauric acid, palmitic acid, stearic acid, behenic acid, arichidonic acid, oleic acid, isostearic acid, sebacic acid, or combinations thereof.

[0098] In some embodiments, fatty acid esters or fatty alcohol esters may be selected. For example, esters of saturated or unsaturated, linear or branched C1-C26 aliphatic mono- or poly-acids and saturated or unsaturated, linear or branched C1-C26 aliphatic mono- or poly-alcohols, the total carbon number of the esters being more particularly greater than or equal to 10, may be used. In other embodiments, esters of C4-C22 dicarboxylic or tricarboxylic acids and C1-C22 alcohols and esters of mono-, di- or tri-carboxylic acids and C2-C26 di-, tri-, tetra- or penta-hydroxy alcohols may also be used.By way of non-limiting examples, isostearyl lactate, lauryl lactate, linoleyl lactate, oleyl lactate, (iso)stearyl octanoate, isocetyl octanoate, octyl octanoate, cetyl octanoate, decyl oleate, isocetyl isostearate, isocetyl laurate, isocetyl stearate, isodecyl octanoate, isodecyl oleate, isononyl isononanoate, isostearyl palmitate, methyl acetylricinoleate, myristyl stearate, octyl isononanoate, isononanoate 2-ethylhexyl, octyl palmitate, octyl pelargonate, octyl stearate, octyldodecyl erucate, oleyl erucate, ethyl and isopropyl palmitates, 2-ethylhexyl palmitate, 2-octyldecyl palmitate, alkyl myristates such as isopropyl, butyl, cetyl, 2-octyldodecyl, myristyl or stearyl myristate, hexyl stearate, stearate. butyl, isobutyl stearate, dioctyl malate, hexyl laurate, 2-hexyldecyl laurate, diethyl sebacate, diisopropyl sebacate, diisopropyl adipate, di-n-propyl adipate, dioctyl adipate, diisostearyl adipate, dioctyl maleate, glyceryl undecylenate, octyldodecyl stearoylstearate, pentaerythrityl monoricinoleate, pentaerythrityl tetraisononanoate, pentaerythrityl tetrapelargonate, pentaerythrityl tetraisostearate, pentaerythrityl tetraoctanoate, propylene glycol dicaprylate, dicaprate propylene glycol, tridecyl erucate, triisopropyl citrate, triisostearyl citrate, glyceryl trilactate, glyceryl trioctanoate, trioctyldodecyl citrate, trioleyl citrate, propylene glycol dioctanoate, neopentyl glycol diheptanoate, diethylene glycol diisononanoate,and / or polyethylene glycol distearates may be selected. In a preferred embodiment, the composition comprises at least one fatty acid ester and / or one fatty alcohol ester, for example pentaerythrityl tetraisostearate.

[0099] In some embodiments, the treatment compositions comprise at least one wax. Non-limiting examples of waxes that may be used include beeswax, hydrogenated olive alkyl esters, camauba wax, candelilla wax, ouricoury wax, Japan wax, cork fiber wax or sugarcane wax, rice wax, rice bran wax, montan wax, paraffin wax, lignite wax or microcrystalline wax, ceresin or ozokerite, hydrogenated palm kernel glycerides / palm glycerides, palm butter, sumac wax, citrus aurantium dulcis (orange) peel wax, theobroma grandiflorum seed butter, helianthus annuus (sunflower) seed wax, siliconyl candellila wax, china wax, cetyl palmitate, lanolin, shellac, spermaceti, cetyl esters, hydrogenated castor wax;triglyceride esters such as tribehenin (glyceryl tribehenate); synthetic waxes such as hydrocarbon waxes and polyethylene waxes obtained by the polymerization or copolymerization of ethylene, polypropylene waxes, or mixtures of two or more of any of these waxes. In certain preferred embodiments, the treatment compositions comprise a wax component that comprises, consists essentially of, or consists of cetyl esters.;

[0100] In some embodiments, the treatment composition comprises one or more fatty compounds selected from oils of animal, vegetable or mineral origin (e.g., lanolin, squalene, fish oil, perhydrosqualene, mink oil, turtle oil, soybean oil, grapeseed oil, sesame oil, corn oil, rapeseed oil, sunflower oil, cottonseed oil, avocado oil, olive oil, castor oil, jojoba oil, peanut oil, sweet almond oil, palm oil, cucumber oil, hazelnut oil, apricot kernel oil, wheat germ, calophyllum oil, macadamia oil, coconut oil, cereal germ oil, candlenut oil, thistle oil, candelilla oil, safflower oil, or shea butter), linear or branched hydrocarbons (e.g., polybutene, hydrogenated polyisobutene, polyisoprene, polydecenes such as hydrogenated polydecene, or also linear, branched and / or cyclic alkanes which are optionally volatile such as, for example, isohexadecane, isododecane, isodecane or isohexadecane), mono- and / or poly-esters of fatty acids and / or fatty alcohols (e.g., mono- and poly-esters of hydroxy acids and fatty alcohols, esters of benzoic acid and fatty alcohols, polyol polyesters, dipentaerythrityl esters C5-C9, trimethylolpropane polyesters, propylene glycol polyesters, or hydrogenated castor oil polyesters), perfluorinated and / or organofluorinated oils, fluorosilicone oils,or mixtures of two or more thereof. Non-limiting examples of fatty acids that may be used include optionally branched and / or unsaturated fatty acids such as myristic acid, palmitic acid, stearic acid, behenic acid, oleic acid, linoleic acid, linolenic acid, isostearic acid, or mixtures of two or more thereof.

[0101] If present, the total amount of fatty compounds in the treatment composition may range from about 0.1% to about 20%, such as from about 1% to about 20%, from about 2% to about 15%, from about 3% to about 12%, or from about 5% to about 10% by weight, based on the total weight of the composition. In certain preferred embodiments, the treatment compositions comprise at least one fatty compound selected from silicone oils, fatty alcohols, waxes, or combinations thereof, wherein the total amount of fatty compounds in the composition ranges from about 1% to about 20%, preferably from about 2% to about 15%, more preferably from about 3% to about 12%, and most preferably from about 5% to about 10% by weight, based on the total weight of the composition. Thickening Agents

[0102] The treatment compositions that can be used in the methods according to the disclosure optionally comprise at least one thickening agent. Useful thickening agents include, but are not limited to, semi-synthetic polymers, such as semi-synthetic cellulose derivatives, synthetic polymers, such as carbomers, poloxamers and acrylate / beheneth-25 methacrylate copolymers, acrylate copolymers, polyethyleneimines (e.g., PEL10), natural polymers, such as acacia, tragacanth, alginates (e.g., sodium alginate), carrageenan, vegetable gums, such as xanthan gum, guar gum, petroleum jelly, waxes, associated particulate colloids, such as bentonite, colloidal silicon dioxide and microcrystalline cellulose, celluloses such as hydroethylcellulose and hydroxypropylcellulose, and guars such as hydroxypropyl guar.

[0103] In some embodiments, the thickening agent may be selected from associative thickening polymers such as anionic associative polymers, amphoteric associative polymers, cationic associative polymers, or nonionic associative polymers. A non-limiting example of an amphoteric associative polymer is acrylates / beheneth-25 methacrylate copolymer, and non-limiting examples of anionic associative polymers include acrylates copolymer and acrylates-4 crosslinked polymer.

[0104] If present, the total amount of thickening agents may range from about 0.01% to about 8%, for example from about 0.05% to about 5%, from about 0.1% to about 4%, from about 0.2% to about 3%, or from about 0.3% to about 2% by weight, based on the total weight of the composition. Auxiliary components

[0105] The treatment compositions that may be used in the methods according to the disclosure may optionally include one or more auxiliary components. Non-limiting examples include preservatives, fragrances, pH adjusters, salts, antioxidants, vitamins, vitamin derivatives, ceramides, botanical extracts, proteins, protein hydrolysates, protein isolates, hydrotropes, pearlescent agents, buffers, sequestering agents, pigments, dyes (e.g., natural and / or synthetic direct dyes), and the like.

[0106] The total amount of auxiliary components, if present, is typically from about 0.01% to about 10%, based on the total weight of the treatment composition. For example, in some embodiments, the individual amounts of each component or the total amount of components may range from about 0.1% to about 10%, from about 0.1% to about 8%, from about 0.1% to about 5%, from about 0.1% to about 4%, from about 0.1% to about 3%, from about 0.1% to about 2%, from about 1% to about 10%, from about 1% to about 8%, from about 1% to about 5%, from about 1% to about 4%, from about 1% to about 3%, or from about 1% to about 2% by weight, based on the total weight of the treatment composition.

[0107] The treatment compositions that may be used in the methods of the disclosure typically have a pH of less than or equal to about 7, such as about 6 or less, about 5 or less, about 4.5 or less than or equal to about 4. For example, the treatment compositions may have a pH of from about 1 to about 7, such as about 2 to about 6, about 2.5 to about 5.5, about 2.5 to about 5, about 2.5 to about 4.5, or about 3 to about 4. In some embodiments, the pH of the composition may be, for example, about 3, about 3.25, about 3.5, about 3.75, or about 4, including all intermediate ranges and subranges.

[0108] The treatment compositions may be in any suitable form. For example, suitable treatment compositions may be in the form of a liquid, a gel, a gel-cream, a high, medium or low density cream, a serum, a lotion, etc. II. DYE COMPOSITION

[0109] Hair dyeing compositions and methods are well known. It is contemplated that the treatment compositions described herein may be advantageously used in connection with a permanent (oxidative) dyeing process. Typically, an oxidative dye composition is prepared at or about the time of use by mixing a dye base composition comprising oxidative dye compounds with an oxidizing composition, the resulting mixture (the oxidative dye composition) being applied to the hair in the desired manner, allowed to remain for a period of time which may, for example, range from about 10 minutes to about one hour, and then the oxidative dye composition is rinsed from the hair.

[0110] Oxidative dyeing compounds that may be used include oxidation bases that may be optionally combined with one or more couplers. For example, the oxidation bases may be selected from para-phenylenediamines, bis(phenyl)alkylenediamines, para-aminophenols, ortho-aminophenols and heterocyclic bases, and their addition salts.

[0111] Among the para-phenylenediamines which may be mentioned, for example, are para-phenylenediamine, para-toluenediamine, 2-chloro-para-phenylenediamine, 2,3-dimethyl-para-phenylenediamine, 2,6-dimethyl-para-phenylenediamine, 2,6-diethyl-para-phenylenediamine, 2,5-dimethyl-para-phenylenediamine, N,N-dimethyl-para-phenylenediamine, N,N-diethyl-para-phenylenediamine, N,N-dipropyl-para-phenylenediamine, 4-amino-N,N-diethyl-3-methylaniline, N,N-bis([3-hydroxyethyl)-para-phenylenediamine, 4-N,N-bis([3-hydroxyethyl)amino-2-methylaniline, 4-N,N-bis([3-hydroxyethyl)amino-2-chloroaniline, 2-[3-hydroxyethyl-para-phenylenediamine, 2-methoxymethyl-para-phenylenediamine, 2-fluoro-para-phenylenediamine, 2-isopropyl-para-phenylenediamine, N-([3-hydroxypropyl)-para-phenylenediamine, 2-hydroxymethyl-para-phenylenediamine, N,N-dimethyl-3-methyl-para-phenylenediamine, N-ethyl-N-([3-hydroxyethyl)-para-phenylenediamine, N-([3,γ-dihydroxypropyl)-para-phenylenediamine, N-(4'-aminophenyl)-para-phenylenediamine, N-phenyl-para-phenylenediamine, 2-[3-hydroxyethyloxy-para-phenylenediamine, 2-[3-acetylaminoethyloxy-para-phenylenediamine, N-([3-methoxyethyl)-para-phenylenediamine, 4-aminophenylpyrrolidine, 2-thienyl-para-phenylenediamine, 2-[3-hydroxyethylamino-5-aminotoluene and 3-hydroxy-l-(4'-aminophenyl)pyrrolidine, and their acid addition salts.

[0112] Among the above-mentioned para-phenylenediamines, para-phenylenediamine, para-toluenediamine, 2-isopropyl-para-phenylenediamine, 2-[3-hydroxyethyl-para-phenylenediamine, 2-[3-hydroxyethyloxy-para-phenylenediamine, 2,6-dimethyl-para-phenylenediamine, 2,6-diethyl-para-phenylenediamine, 2,3-dimethyl-para-phenylenediamine, N,N-bis([3-hydroxyethyl)-para-phenylenediamine, 2-chloro-para-phenylenediamine and 2-[3-acetylaminoethyloxy-para-phenylenediamine, and their acid addition salts, are particularly preferred.

[0113] Among the bis(phenyl)alkylenediamines which may be mentioned, for example, are N,N'-bis([3-hydroxyethyl)-N,N'-bis(4'-aminophenyl)-1,3-diaminopropanol, N,N'-bis([3-hydroxyethyl)-N,N'-bis(4'-aminophenyl)ethylenediamine, N,N'-bis(4-aminophenyl)tetramethylenediamine, N,N'-bis([3-hydroxyethyl)-N,N'-bis(4-aminophenyl)tetramethylenediamine, N,N'-bis(4-methylaminophenyl)tetramethylenediamine, N,N'-bis(ethyl)-N,N'-bis(4'-amino-3'-methylphenyl)ethylenediamine and 1,8-bis(2,5-diaminophenoxy)-3,6-dioxaoctane, and their addition salts.

[0114] Among the para-aminophenols which may be mentioned, for example, are para-aminophenol, 4-amino-3-methylphenol, 4-amino-3-fluorophenol, 4-amino-3-chlorophenol, 4-amino-3-hydroxymethylphenol, 4-amino-2-methylphenol, 4-amino-2-hydroxymethylphenol, 4-amino-2-methoxymethylphenol, 4-amino-2-aminomethylphenol, 4-amino-2-([3-hydroxyethylaminomethyl)phenol and 4-amino-2-fluorophenol, and their acid addition salts.

[0115] Among the ortho-aminophenols which may be mentioned, for example, are 2-aminophenol, 2-amino-5-methylphenol, 2-amino-6-methylphenol and 5-acetamido-2-aminophenol, and their addition salts.

[0116] Among the heterocyclic bases that may be mentioned, for example, are pyridine derivatives, pyrimidine derivatives and pyrazole derivatives.

[0117] Among the pyridine derivatives that may be mentioned are 2,5-diaminopyridine, 2-(4-methoxyphenyl)amino-3-aminopyridine and 3,4-diaminopyridine, and their addition salts.

[0118] Other pyridine oxidation bases may include the 3-aminopyrazolo[l,5-a]pyridine oxidation bases or their addition salts described, for example, pyrazolo[l,5-a]pyrid-3-ylamine, 2-acetylaminopyrazolo[l,5-a]pyrid-3-ylamine, 2-morpholin-4-ylpyrazolo[l,5-a]pyrid-3-ylamine, 3-aminopyrazolo[l,5-a]pyridine-2-carboxylic acid, 2-methoxypyrazolo[l,5-a]pyrid-3-ylamine, (3-aminopyrazolo[l,5-a]pyrid-7-yl)methanol, 2-(3-aminopyrazolo[l,5-a]pyrid-5-yl)ethanol, 2-(3-aminopyrazolo[l,5-a]pyrid-7-yl)ethanol, (3-aminopyrazolo[l,5-a]pyrid-2-yl)methanol, 3,6-diaminopyrazolo[l,5-a]pyridine, 3,4-diaminopyrazolo[l,5-a]pyridine, pyrazolo[l,5-a]pyridine-3,7-diamine, 7-morpholin-4-ylpyrazolo[l,5-a]pyrid-3-ylamine, pyrazolo[l,5-a]pyridine-3,5-diamine, 5-morpholin- 4-ylpyrazolo[l,5-a]pyrid-3-ylamine, 2-[(3-aminopyrazolo[l,5-a]pyrid-5-yl)(2-hydroxyethyl)amino]ethanol, 2-[(3-aminopyrazolo[l,5-a]pyrid-7-yl)(2-hydroxyethyl)amino]ethanol, 3-aminopyrazolo[l,5-a]pyridin-5-ol, 3-aminopyrazolo[l,5-a]pyridin-4-ol, 3-aminopyrazolo[l,5-a]pyridin-6-ol, 3-aminopyrazolo[l,5-a]pyridin-7-ol, 2-[3-hydroxyethoxy-3-amino-pyrazolo[l,5-a]pyridine; 2-(4-dimethylpiperazinium-l-yl)-3-amino-pyrazolo[l,5-a]pyridine; and their addition salts.

[0119] More particularly, the oxidation bases may be chosen from 3-aminopyrazolo-[1,5-a]-pyridines and preferably substituted on the carbon atom 2 with: a (di)(C1-C6 alkyl)amino group in which said alkyl group may be substituted with at least one hydroxy, amino, imidazolium group; a heterocycloalkyl group containing from 5 to 7 members, and from 1 to 3 heteroatoms, potentially cationic, potentially substituted with one or more alkyls (C1-C6), such as a di(C1-C4 alkyl)piperazinium; or an alkoxy (C1-C6) potentially substituted with one or more hydroxy groups, such as an α-hydroxyalkoxy, and their addition salts.

[0120] Among the pyrimidine derivatives that may be mentioned are compounds such as 2,4,5,6-tetraaminopyrimidine, 4-hydroxy-2,5,6-triaminopyrimidine, 2-hydroxy-4,5,6-triaminopyrimidine, 2,4-dihydroxy-5,6-diaminopyrimidine, 2,5,6-triaminopyrimidine and their addition salts and tautomeric forms, when a tautomeric equilibrium exists.

[0121] Among the pyrazole derivatives that may be mentioned are compounds such as 4,5-diamino-1-methylpyrazole, 4,5-diamino-1-([3-hydroxyethyl)pyrazole, 3,4-diaminopyrazole, 4,5-diamino-1-(4'-chlorobenzyl)pyrazole, 4,5-diamino-1,3-dimethylpyrazole, 4,5-diamino-3-methyl-1-phenylpyrazole, 4,5-diamino-1-methyl-3-phenylpyrazole, 4-amino-1,3-dimethyl-5-hydrazinopyrazole, 1-benzyl-4,5-diamino-3-methylpyrazole, 4,5-diamino-3-tert-butyl-1-methylpyrazole, 4,5-diamino-l-tert-butyl-3-methylpyrazole, 4,5-diamino-l-([3-hydroxyethyl)-3-methylpyrazole, 4,5-diamino-l-ethyl-3-methylpyrazole, 4,5-diamino-l-ethyl-3-(4'-methoxyphenyl)pyrazole, 4,5-diamino-l-ethyl-3-hydroxymethylpyrazole, 4,5-Diamino-3-hydroxymethyl-l-methylpyrazole, 4,5-Diamino-3-hydroxymethyl-l-isopropylpyrazole, 4,5-Diamino-3-methyl-l-isopropylpyrazole, 4-amino-5-(2'-aminoethyl)amino-l,3-dimethylpyrazole, 3,4,5-triaminopyrazole, l-methyl-3,4,5-triaminopyrazole, 3,5-Diamino-l-methyl-4-methylaminopyrazole, 3,5-Diamino-4-(P-hydroxyethyl)amino-l-methylpyrazole, and their addition salts. 4,5-Diamino-l-(-methoxyethyl)pyrazole may also be used.

[0122] Pyrazole derivatives which may also be mentioned include diamino-N,N-dihydropyrazolopyrazolones, such as the following compounds and their addition salts: 2,3-diamino-6,7-dihydro-1H,5H-pyrazolo[1,2-a]pyrazol-1-one, 2-amino-3-ethylamino-6,7-dihydro-1H,5H-pyrazolo[1,2-a]pyrazol-1-one, 2-amino-3-isopropylamino-6,7-dihydro-1H,5H-pyrazolo[1,2-a]pyrazol-1-one, 2-amino-3-(pyrrolidin-1-yl)-6,7-dihydro-1H,5H-pyrazolo[1,2-a]pyrazol-1-one, 4,5-diamino-1,2-dimethyl-1,2-dihydropyrazol-3-one, 4,5-diamino-1,2-diethyl-1,2-dihydropyrazol-3-one, 4,5-diamino-1,2-di-(2-hydroxyethyl)-1,2-dihydropyrazol-3-one, 2-amino-3-(2-hydroxyethyl)amino-6,7-dihydro-lH,5H-pyrazolo[l,2-a]pyrazol-l-one, 2-amino-3-dimethylamino-6,7-dihydro-lH,5H-pyrazolo[l,2-a]pyrazol-lo ne, 2,3-diamino-5,6,7,8-tetrahydro-lH,6H-pyridazino[l,2-a]pyrazol-l-one, 4-amino-1,2-diethyl-5-(pyrrolidin-l-yl)-1,2-dihydropyrazol-3-one, 4-amino-5-(3-dimethylaminopyrrolidin-1 -yl)-1,2-diethyl-1,2-dihydropyrazol-3-one, 2,3-diamino-6-hydroxy-6,7-dihydro-1H,5H-pyrazolo[1,2-a]pyrazol-1-one. ,

[0123] 4,5-Diamino-l-(-hydroxyethyl)pyrazole and / or 2,3-diamino-6,7-dihydro-lH,5H-pyrazolo[l,2-a]pyrazol-l-one and / or one of their salts may be used as heterocyclic bases.

[0124] The dyeing compositions which may be used may optionally further comprise one or more couplers. Among these couplers, mention may be made in particular of meta-phenylenediamines, meta-aminophenols, meta-diphenols, naphthalene-based couplers and heterocyclic couplers, and their addition salts.

[0125] Mention may be made, for example, of 2-methyl-5-aminophenol, 5-N-(B-hydroxyethyl)amino-2-methylphenol, 3-aminophenol, 5-amino-6-chloro-o-cresol (3-amino-2-chloro-6-methylphenol), 1,3-dihydroxybenzene, 1,3-dihydroxy-2-methylbenzene, 4-chloro-1,3-dihydroxybenzene, 2,4-diamino-l-(B-hydroxyethyloxy)benzene, 2-amino-4-(B-hydroxyethylamino)-l-methoxybenzene, 1,3-diaminobenzene, l,3-bis(2,4-diaminophenoxy)propane, 3-ureidoaniline, 3-ureido-l-dimethylaminobenzene, sesamol, 1B-hydroxyethylamino-3,4-methylenedioxybenzene, α-naphthol, 2-methyl-1-naphthol, 6-hydroxyindole, 4-hydroxyindole, 4-hydroxy-N-methylindole, 2-amino-3-hydroxypyridine, 6-hydroxybenzomorpholine, 3,5-diamino-2,6-dimethoxypyridine, lN-(B-hydroxyethyl)amino-3,4-methylenedioxybenzene, 2,6-bis(B-hydroxyethylamino)toluene, 6-hydroxyindoline, 2,6-dihydroxy-4-methylpyridine, lH-3-methylpyrazol-5-one, l-phenyl-3-methylpyrazol-5-one, 2,6-dimethylpyrazolo[l,5-b]-l,2,4-triazole, 2,6-dimethyl[3,2-c]-l,2,4-triazole and 6-methylpyrazolo[l,5-a]benzimidazole, their acid addition salts, and mixtures thereof.

[0126] In general, the addition salts of the oxidation bases and couplers which can be used in the context of the invention are specially selected from addition salts with an acid, such as hydrochlorides, hydrobromides, sulfates, citrates, succinates, tartrates, lactates, tosylates, benzenesulfonates, phosphates and acetates.

[0127] The oxidizing base(s) may be present in a total amount ranging from about 0.001% to about 10%, such as from about 0.001% to about 5%, from about 0.001% to about 3%, from about 0.001% to about 2%, from about 0.001% to about 1%, from about 0.005% to about 5%, from about 0.005% to about 3%, from about 0.005% to about 2%, from about 0.005% to about 1%, from about 0.01% to about 5%, from about 0.01% to about 3%, from about 0.01% to about 2%, or from about 0.01% to about 1%, by weight, based on the total weight of the dye base. oxidative or oxidative dye composition.The coupler(s), if present, may be present in a total amount ranging from about 0.001% to about 10%, such as from about 0.001% to about 5%, from about 0.001% to about 3%, from about 0.001% to about 2%, from about 0.001% to about 1%, from about 0.005% to about 5%, from about 0.005% to about 3%, from about 0.005% to about 2%, from about 0.005% to about 1%, from about 0.01% to about 5%, from about 0.01% to about 3%, from about 0.01% to about 2%, or from about 0.01% to about 1%, by weight, based on the total weight of the oxidative dye base or the oxidative dye composition.

[0128] Before applying the oxidative dye base composition to the hair, it is generally mixed with an oxidizing composition comprising at least one oxidizing agent and a suitable cosmetic carrier, for example water. Typically, the oxidizing compositions may comprise additional components such as, for example, rheology modifying agents, chelators, fatty substances, ceramides, pH correcting agents, amino acids, carboxylic acids, preservatives, perfumes, surfactants, etc. The oxidizing agent may be, for example, hydrogen peroxide, urea peroxide, alkali metal bromates, alkali metal ferricyanides, or persalts, such as perborates or persulfates. The total amount of oxidizing agent and carrier may vary depending on the desired strength of the oxidizing composition. For example, the total amount of oxidizing agent may be from about 1% to about 40%, such as from about 1% to about 30%, from about 1% to about 20%, from about 1% to about 15%, from about 1% to about 12%, from about 3% to about 20%, from about 3% to about 15%, from about 3% to about 12%, from about 5% to about 20%, from about 5% to about 15%, from about 5% to about 12%, from about 7% to about 20%, from about 7% to about 15%, from about 7% to about 12%, from about 9% to about 20%, from about 9% to about 15%, or from about 9% to about 12% by weight, based on the total weight of the oxidizing composition. In some cases, the oxidizing composition is aqueous and the oxidizing agent comprises, consists essentially of, or consists of hydrogen peroxide.For example, the hydrogen peroxide may be present in an amount ranging from about 5% to about 20%, such as from about 7% to about 15%, from about 8% to about 13%, from about 8% to about 10%, from about 9% to about 13%, or from about 10% to about 12%, for example, about 7%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, or about 15% by weight, based on the total weight of the oxidizing composition. The oxidizing composition may be, for example, 20V, 30V, or 40V hydrogen peroxide compositions.

[0129] The oxidative dye base composition is typically mixed with an oxidizing composition at a ratio of from about 1:5 to about 5:1, such as about 1:4 to about 4:1, about 1:3 to about 3:1, or about 1:2 to about 2:1, or is, for example, about 5:1, about 4:1, about 3:1, about 2:1, about 1.5:1, about 1:1, about 1:1.5, about 1:2, about 1:3, about 1:4, or about 1:5, generally at or about the time of use, to form the bleaching composition. The mixture is generally alkaline, with a pH greater than about 7, such as greater than about 8, greater than about 9, or greater than about 10, for example from about 7 to about 10.5, or from about 7.5 to about 10.Typically, once the mixture is prepared, it is applied to hair that may be damp, wet or dry, optionally covered (e.g., with film), optionally heated (e.g., with a hair dryer or hair dryer hood) and, after sufficient processing time to obtain the desired color, the hair is rinsed.

[0130] Although the aforementioned oxidative dye base compositions, oxidative compositions, and hair dyeing processes are disclosed for use in the methods of the disclosure, those skilled in the art will understand that variations of hair dyeing compositions and processes may be also be used. Thus, the aforementioned dyeing compositions and processes are not intended to limit the methods according to the disclosure.

[0131] III. METHODS FOR TREATING KERATIN FIBERS

[0132] The disclosure relates to methods of treating keratin fibers with a treatment composition according to the disclosure in connection with a hair dyeing process. The methods include applying a treatment composition to the hair, optionally leaving the composition on the hair for a period of time ("treatment time", "rest period", or "lay-in period"), and optionally rinsing the composition from the hair. The treatment composition may be applied to the hair before and / or after applying a hair dye composition to the hair, or may be applied to the hair simultaneously with a hair dye composition.

[0133] Although not necessary, the methods according to the disclosure may also include a step of heating the hair to which the treatment composition has been applied, for example during the resting period while the treatment composition is on the hair. For example, a hair dryer, a hair dryer hood, etc., may be used.

[0134] The period of time the treatment composition is left on the hair may be a suitable time to allow the active agents to provide benefits to the keratin fibers, such as about 30 seconds, about 1 minute, about 2 minutes, about 5 minutes, about 10 minutes, about 15 minutes, about 20 minutes, about 30 minutes, about 45 minutes, about 1 hour, about 2 hours, etc., or may vary by a period of time using any of the foregoing values ​​as upper and lower limits.By way of non-limiting example, the exposure period may range from about 30 seconds to about 60 minutes, from about 30 seconds to about 45 minutes, from about 30 seconds to about 30 minutes, from about 30 seconds to about 20 minutes, from about 30 seconds to about 15 minutes, from about 30 seconds to about 10 minutes, from about 30 seconds to about 5 minutes, from about 1 minute to about 60 minutes, from about 1 minute to about 45 minutes, from about 1 minute to about 30 minutes, from about 1 minute to about 20 minutes, from about 1 minute to about 15 minutes, from about 1 minute to about 10 minutes, from about 1 minute to about 5 minutes, from about 2 minutes to about 60 minutes, from about 2 minutes to about 45 minutes, from about 2 minutes to about 30 minutes, from about 2 minutes to about 20 minutes, from about 2 minutes to about 15 minutes, from about 2 minutes to about 10 minutes, from about 2 minutes to about 5 minutes, etc.

[0135] The period of time the dye composition is left on the hair may be a suitable time to achieve the desired color, which can range from about 1 minute to about 60 minutes, such as from about 3 minutes to about 45 minutes, from about 5 minutes to about 30 minutes, or from about 10 minutes to about 20 minutes.

[0136] In exemplary embodiments, a treatment composition according to the disclosure may be applied to the hair before, during, and / or after the application of a dye composition, with or without an intermediate rinse. For example, such a method may include applying a treatment composition according to the disclosure to wet, damp, or dry hair, leaving the composition on the hair for an appropriate processing time, optionally rinsing the hair, and then substantially immediately thereafter (i.e., as part of the same hair dyeing process), with or without an intermediate rinse of the hair, applying a hair dye composition to the hair.Another exemplary method may include applying a dye composition to the hair, and substantially immediately thereafter (i.e., as part of the same hair dyeing process), with or without intervening rinsing of the hair, applying to the hair a treatment composition according to the disclosure. In either of the preceding exemplary embodiments, the treatment composition and the dye composition may optionally be layered one upon the other on the hair (leave-on), or may optionally be applied to the hair in alternating layers (rinsing) during the hair dyeing process.As a further exemplary method, a treatment composition according to the disclosure may be added or mixed with a hair dye composition, e.g., an oxidative dye base composition, an oxidative composition, or a mixture thereof, at or about the time of use. In yet another exemplary method, a treatment composition and a dye composition may be applied simultaneously to the hair, e.g., by means of a dual-chamber applicator that is configured to dispense two compositions at the same time. Thus, it is contemplated that the treatment compositions according to the disclosure may be incorporated into a hair dyeing process, thereby reducing, minimizing, or preventing damage to the hair that might otherwise result from such harsh chemical treatments.

[0137] As a non-limiting example of hair dyeing methods according to the disclosure, a treatment composition as described herein may be applied to wet, damp, or dry hair and then allowed to remain for a treatment period as described herein, for example, from about one minute to about two hours, such as from about five minutes to about one hour, optionally with heating. The hair may then be rinsed, and then a hair dye composition may be applied to the hair. is applied according to conventional hair dyeing routines. As a further non-limiting example of hair dyeing methods according to the disclosure, a treatment composition as described herein may be applied to wet, damp, or dry hair and then allowed to remain for a setting period as described herein, for example, from about one minute to about two hours, such as from about five minutes to about one hour, optionally with heating. Without rinsing the treatment composition from the hair, a dye composition may be applied to the hair, and then the hair dyeing process is carried out according to conventional hair dyeing routines.

[0138] As another non-limiting example of hair dyeing methods according to the disclosure, a hair dye composition may be applied to the hair to dye the hair according to conventional dyeing routines. The hair may then be rinsed, a treatment composition as described herein is applied to damp, wet, or dry hair and then allowed to remain for a setting period as described herein, for example, from about one minute to about two hours, such as from about five minutes to about one hour, optionally with heating. The hair may then be rinsed. As another non-limiting example of hair dyeing methods according to the disclosure, a hair dye composition may be applied to the hair according to conventional hair dyeing routines.Without rinsing the hair dye composition, a treatment composition as described herein may be applied to wet, damp, or dry hair and then allowed to remain for a processing period as described herein, for example, from about one minute to about two hours, such as from about five minutes to about one hour, optionally with heating. The hair may then be rinsed.

[0139] Surprisingly, hair that has been treated with treatment compositions and methods according to the disclosure before, during, and / or after the dyeing process exhibits less damage than hair dyed untreated with treatment compositions and methods according to the disclosure before, during, and / or after the dyeing process. The hair may have lower elasticity and / or higher tensile strength than similarly dyed hair not treated according to the disclosure. Thus, additional methods according to the disclosure include methods of reducing or minimizing hair damage in a hair dyeing process, methods of preventing hair damage with respect to a hair dyeing process, and methods of improving hair elasticity and / or tensile strength in a hair dyeing process.

[0140] Having described in detail the numerous embodiments of the present invention, it will be apparent that modifications and variations are possible without departing from the scope of the disclosure defined in the appended claims. Furthermore, it should be noted that all examples of the present disclosure, while illustrating numerous embodiments of the disclosure, are provided by way of non-limiting examples and therefore should not be construed as limiting the various aspects thus illustrated. It should be understood that all definitions are provided herein only for the purposes of this disclosure.

[0141] As used herein, treating hair with a treatment composition or applying a treatment composition to hair that is "in connection with a hair dyeing process," "as part of the same hair dyeing process," and variations thereof, are intended to convey that the treatment composition is applied to the hair in close proximity to when the hair is subjected to a hair dyeing process, such that one skilled in the art would consider the processes of treating hair with a treatment composition as described herein and dyeing hair as a single process.For example, the treatment composition may be applied to the hair less than 24 hours, such as less than 12 hours, less than 6 hours, less than 4 hours, less than 3 hours, less than 2 hours, less than 1 hour, less than 45 minutes, less than 30 minutes, or less than 15 minutes before and / or after applying a hair dye composition to the hair.

[0142] In the present application, the use of the singular includes the plural, unless specifically indicated otherwise. The singular forms "a", "an", "the", "the" and "at least one" are understood to encompass the plural as well as the singular, unless the context clearly indicates otherwise. The expression "one or more" means "at least one" and therefore includes individual components as well as mixtures / combinations. Similarly, the expression "one of their salts" also concerns "their salts".Thus, when the disclosure refers to "an element selected from the group consisting of A, B, C, D, E, F, a salt thereof or mixtures thereof", it indicates that one or more of A, B, C, D and F may be included, that one or more of a salt of A, a salt of B, a salt of C, a salt of D, a salt of E and a salt of F may be included, or that a mixture of any two of A, B, C, D, E, F, a salt of A, a salt of B, a salt of C, a salt of D, a salt of E and a salt of F may be included.

[0143] The expression "and / or" should be understood to include both the conjunctive and the disjunctive. For example, "amino acids and / or their salts" means "amino acids and their salts" as well as "amino acids or their salts", and expressly covers either.

[0144] As used herein, the term "salts" throughout the disclosure may include salts having a counterion such as an alkali metal, alkaline earth metal, or ammonium counterion. This list of counterions, however, is not limiting. Salts also include a dissociated form of a compound, for example in an aqueous solution.

[0145] Unless expressly stated otherwise, “approximately” means + / - 5%.

[0146] As used herein, if a component is described as being present "in an amount less than or equal to" a certain amount, it is intended that that component be present in the composition, i.e., be present in an amount greater than 0%.

[0147] All quantities stated herein are relative to the amount of active ingredient unless otherwise stated.

[0148] All percentages, parts and ratios herein are based on the total weight of the compositions of the present disclosure, unless otherwise indicated.

[0149] In the present application, the terms "keratin fibers" and "hair" are used interchangeably, without the intention of being limiting. Those skilled in the art will understand that keratin fibers include hair, such as hair growing on the scalp, which is frequently dyed in a cosmetic process to alter the appearance of the hair.

[0150] As used herein, the term "applying a composition to the hair," and variations thereof, is intended to mean contacting the hair with at least one of the compositions described herein, in any manner. It may also mean contacting the hair in an effective amount.

[0151] The term "treating the hair" (and its grammatical variations) as used herein refers to applying the compositions described herein to the surface of the hair. The term "treating the hair" (and its grammatical variations) as used herein also refers to contacting the hair with the compositions described herein.

[0152] Unless otherwise defined for any specific embodiment, the term "substantially free" or "essentially free" as used herein means that there is less than about 5% by weight of a specific material added to a composition, based on the total weight of the composition. For example, compositions may include less than about 4%, less than about 3%, less than about 2%, less than about 1.5%, less than about 1%, less than about 0.5%, less than about 0.1%, less than about 0.01%, less than about 0.001%, or less than about 0.0001% of the specified material. A composition that is "free" of a component is intended to contain no amount of the specified component. However, it is understood that the terms "free" and "substantially free" refer to the amount of a component added to the composition, without including an amount of the component present in the composition as a minor component in a raw material.

[0153] The following examples serve to illustrate embodiments of the present disclosure without being limiting in nature. It will be apparent to those skilled in the art that various modifications and variations may be made in the compositions and methods of the invention without departing from the spirit and scope of the invention. Thus, it is intended that the present disclosure cover modifications and variations that fall within the scope of the appended claims and their equivalents. EXAMPLES

[0154] The following examples are intended to be non-limiting and explanatory in nature only. In the Examples, unless otherwise indicated, the amounts are expressed as a percentage by weight (% by weight) of active ingredients, relative to the total weight of the composition. Example 1 - Treatment compositions

[0155] Compositions IA to IG, which may be used in the methods according to the disclosure, were prepared as shown in Table 1. The pH of each of compositions IA to IG was about 3.5.

[0156] [Table 1] TABLE 1 IA IB IC 1D 1E 1F IG Basic amino acid(s) 5.0 5.0 5.0 5.0 5.0 5.0 2.0 Glycine betaine 2.5 2.5 2.5 2.5 2.5 2.5 2.5 Citric and / or lactic acid 6.1 6.1 6.1 6.1 6.1 6.1 4.1 Neutral amino acid(s) 0.5 Preservatives 0.5 0.5 0.5 0.5 0.5 0.5 0.5 Solvents (water and non-aqueous solvents) QS QS QS QS QS QS QS

[0157] Compositions IA to IG, which included a synergistic combination of components (carboxylic acids (citric and / or lactic acid), osmolytes (glycine betaine) and amino acids (arginine and / or serine)), may be used in methods according to the disclosure, for example may be applied to the hair before and / or after applying a dyeing composition to the hair, may be mixed with a dyeing composition, or may be applied to the hair simultaneously with a dyeing composition, and are expected to minimize, prevent, and / or repair damage to the hair that would otherwise be expected from a hair dyeing process. The treatment compositions are also expected to improve the elasticity and strength of the treated hair fibers. Example#!#- Treatment compositions

[0158] Compositions 2A to 2E, which can be used in the methods according to the disclosure, were prepared as shown in Table 2.

[0159] [Table 2] TABLE 2 2A 2B 2C 2D 2E Basic amino acid(s) 5.0 5.0 5.0 5.0 5.0 Glycine betaine 2.5 2.5 2.5 2.5 2.5 Citric acid 6.1 6.1 6.1 6.1 6.1 Silicone oil(s) (dimethicone and / or amodimethicone) 3.3 3.3 3.3 3.3 1.0 Fatty alcohol(s) (stearyl alcohol and / or cetearyl alcohol) 4.5 4.5 6.0 5.0 6.0 Cetyl esters 1.0 Cationic surfactant(s) (cetrimonium chloride, behentrimonium chloride and / or stearamidopropyl dimethylamine) ne) 1.6 1.6 1.6 2.5 1.6 Cocamidopropyl betaine 1.1 1.1 1.1 0.2 Hydroxyethylcellulose 0.8 1.0 1.5 1.5 0.4 Auxiliary component(s) (pH regulators, preservatives, vitamins, extracts) <2 <2 <2 <2 <2 Solvents (water and non-aqueous solvents) QS QS QS QS QS Measured pH 3.7 3.7 3.7 3.7 4.0

[0160] Compositions 2A to 2E, which included a synergistic combination of components (carboxylic acids (citric acid), osmolytes (glycine betaine) and amino acids (arginine)), can be used in methods according to the disclosure, for example, may be applied to the hair before and / or after applying a dye composition to the hair, may be mixed with a dye composition, or may be applied to the hair simultaneously with a dye composition, and are expected to minimize, prevent, and / or repair damage to the hair that would otherwise be expected from a hair dyeing process. The treatment compositions are also expected to improve the elasticity and strength of the treated hair fibers. Example 3 - Treatment compositions

[0161] Treatment compositions 3A to 3D, which may be used in the methods according to the disclosure, were prepared as shown in Table 3.

[0162] [Table 3] TABLE 3 3A 3B 3C 3D Basic amino acid(s) 5.50 5.50 3.80 3.80 Thickening agent(s) 0.30 0.90 0.90 Non-ionic surfactant(s) 0.30 1.50 0.50 0.50 Amphoteric surfactant(s) 0.30 Conditioning agent(s) 0.80 Cationic surfactant(s) 2.10 3.84 3.00 3.00 Glycine betaine 2.50 2.50 1.80 1.80 Citric acid 6.00 6.00 5.50 5.50 Wax(s) 0.50 0.50 Fatty alcohol(s) 6.30 6.30 Vegetable oil(s) 0.50 Fatty acid ester(s) 2.50 1.50 Additives (preservatives, perfume) <2 <2 <2 <2 Solvents (water and non-aqueous solvents) QS QS QS QS

[0163] Compositions 3A to 3D, which included a synergistic combination of components (carboxylic acids (citric acid), osmolytes (glycine betaine) and amino acids (arginine)), may be used in methods according to the disclosure, e.g. may be applied to the hair before and / or after applying a dye composition to the hair, may be mixed with a dye composition, or may be applied to the hair simultaneously with a dye composition, and are expected to minimize, prevent and / or repair damage to the hair that would otherwise be expected from a dyeing process. hair. Treatment compositions should also improve the elasticity and strength of treated hair fibers.

[0164] Example 4 - Additional Treatment Compositions

[0165] The following additional treatment compositions may also be prepared, and should also minimize, prevent, or similarly repair hair damage when used in connection with hair dyeing processes as described herein. The compositions should also improve the elasticity and strength of the treated hair fibers.

[0166] [Table 4] TABLE 4 4A 4B 4C 4D 4E Arginine 2.0 9.8 2.5 Lysine 2.5 2.0 10 Valine betaine 2.0 4.5 2.0 1.0 4.0 Citric acid 3 2.0 9.8 Lactic acid 2.0 10 2 Serine 0.05 0.5 0.05 0.5 Fatty compounds 10 8.0 9.0 15 Cationic and / or amphoteric surfactant(s) 3.0 0.5 2.5 5.0 Additional component(s) (e.g. pH adjusters, vitamins, preservatives, extracts, thickeners) <5 <5 <5 <5 <5 Solvents (water and / or non-aqueous solvents) QS QS QS QS QS

Claims

Claims

1. A method of treating keratin fibers, the method comprising: (i) applying to the keratin fibers a treatment composition comprising: a. at least one compound selected from amino acids or their salts; b. at least one osmolyte; c. at least one compound selected from carboxylic acids or their salts; and d. at least one solvent, and (ii) applying to the keratin fibers a hair dye composition comprising at least one oxidative dyeing compound, wherein step (i) takes place before, during and / or after step (ii).

2. The method of claim 1, wherein the treatment composition comprises at least one osmolyte selected from valine betaine, glutamic acid betaine, glutamine betaine, trimethyllysine, glycine betaine, histidine betaine, N-methylhistidine betaine, alanine betaine, beta-alanine betaine, choline sulfate, pipecolic acid betaine, proline betaine, hydroxyproline betaine, tyrosine betaine, phenylalanine betaine, tryptophan betaine, leucine betaine, isoleucine betaine, their salts, or combinations of two or more thereof, preferably comprising glycine betaine.

3. A method according to any one of claims 1 and 2, wherein the total amount of osmolytes present in the treatment composition ranges from about 0.5% to about 10%, preferably from about 1% to about 8%, more preferably from about 1% to about 5%, most preferably from about 1.5% to about 3.5% by weight, based on the total weight of the composition.

4. A method according to any one of claims 1 to 3, wherein the treatment composition comprises at least one amino acid selected from arginine, glycine, proline, methionine, serine, lysine, histidine, their salts, or combinations of two or more thereof.

5. A method according to any one of claims 1 to 4, wherein the total amount of amino acids and their salts present in the treatment composition ranges from about 2% to about 15%, preferably from about 2.5% to about 12%, more preferably from about 3% to about 10%, most preferably from about 3.5% to about 8% by weight, relative to the total weight of the composition.

6. A method according to any one of claims 1 to 5, wherein the treatment composition comprises at least one carboxylic acid selected from formic acid, acetic acid, propionic acid, butyric acid, valeric acid, caproic acid, enanthic acid, caprylic acid, lactic acid, oxalic acid, malonic acid, malic acid, glutaric acid, citraconic acid, succinic acid, adipic acid, tartaric acid, fumaric acid, maleic acid, citric acid, isocitric acid, aconitic acid, propane-1,2,3-tricarboxylic acid, their salts, or combinations of two or more thereof.

7. A method according to any one of claims 1 to 6, wherein the hair dye composition comprises at least one oxidation base selected from para-phenylenediamines, bis(phenyl)alkylenediamines, para-aminophenols, ortho-aminophenols and heterocyclic bases, their salts, or combinations of two or more thereof.

8. A method according to any one of claims 1 to 7, wherein the hair dye composition comprises at least one coupling compound.

9. A method according to any one of claims 1 to 8, wherein step (i) occurs before step (ii), and the hair is optionally rinsed after step (i) and before step (ii).

10. A method according to any one of claims 1 to 9, wherein step (ii) occurs before step (i), and the hair is optionally rinsed after step (ii) and before step (i).